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Abstract 
 
Introduction: The global obesity epidemic has been associated with various metabolic 
disorders, including insulin resistance and non-alcoholic fatty liver disease (NAFLD). Insulin 
resistance is thought be a hallmark of NAFLD, which is an established risk factor for the 
development of type 2 diabetes mellitus (T2DM) and cardiac dysfunction. Conversely, 
evidence exists to suggest that NAFLD can develop despite conserved insulin sensitivity, and 
that it can play a role in the development of insulin resistance. While both insulin resistance 
and NAFLD are known to contribute to cardiac dysfunction, it is not evident which develops 
first. With the rising burden of obesity-related heart disease, it is vital to gain a better 
understanding of the pathophysiology involved in order to better treat or prevent heart failure. 
 
Aim: To investigate the order of onset of NAFLD and insulin resistance in obesity-induced 
cardiac dysfunction. 
 
Methods: Six- to fifteen-week-old male leptin receptor deficient (Leprdb/db) mice and their lean 
littermate controls (Leprdb/+) were monitored weekly to measure fasting blood glucose and 
body weight. Heart function was determined weekly using TDI echocardiography, after which 
8 animals per group were terminated. Serum was collected to measure lipogram and liver 
enzymes, while muscle, liver and heart tissue were used to investigate insulin resistance, 
NAFLD, and cardiac dysfunction, respectively.  
 
Results: Data obtained showed that Leprdb/db mice had increased body weight (31.75 g ± 0.71 
vs. 20.50 g ± 0.55, p < 0.001) and total cholesterol (3.90 mmol/L ± 0.14 vs. 1.90 mmol/L ± 
0.04, p < 0.001) by 6 weeks of age. Serum AST/ALT ratio (0.76 ± 0.07) indicated hepatic lipid 
accumulation by 7 weeks and histological analysis confirmed the presence of NAFLD at this 
time, as well as its progression in severity with age. Gene expression analysis in the liver 
showed an increase in lipogenic genes FASN (1.16 ± 0.18 vs. 0.25 ± 0.05, p < 0.01) and SCD1 
(1.03 ± 0.08 vs. 0.20 ± 0.05, p < 0.001) by 7 weeks of age. Muscle insulin resistance was not 
present at the onset of NAFLD, and developed around 10 weeks of age, as confirmed by a 
decrease in pPI3K and pAKT protein expression (0.17 ± 0.03 vs 0.10 ± 0.01, p < 0.01 and 
0.23 ± 0.06 vs 0.12 ± 0.03, p < 0.05, respectively). Gene expression analysis confirmed an 
increase in oxidative stress NOX4 (1.23 ± 0.30 vs. 0.77 ± 0.09, p < 0.05), inflammation NFκB 
(1.68 ± 0.09 vs. 0.69 ± 0.04, p < 0.001) and apoptosis CASP3 (1.42 ± 0.10 vs. 1.06 ± 0.06, p 
< 0.05) in the heart of Leprdb/db mice by 10 weeks.  
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Conclusion: Hepatic steatosis preceded muscle insulin resistance in a genetic model of 
obesity, and likely contributed to the development of insulin resistance and myocardial 
dysfunction. 
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Opsomming 
 
Inleiding: Die wêreldwye vetsug epidemie is geassosieer met verskeie metabolies afwykings, 
insluitend insulien weerstandigheid en nie-alkoholiese vetterige lewer siekte (NAFLD). 
Insulien weerstandigheid word beskou as 'n kenmerk van NAFLD, wat 'n gevestigde 
risikofaktor is vir die ontwikkeling van tipe 2 diabetes mellitus (T2DM) en kardiale disfunksie. 
Daarenteen bestaan bewyse dat NAFLD kan ontwikkel ondanks die behoud van insulien 
sensitiwiteit, en dat dit 'n rol kan speel in die ontwikkeling van insulien weerstandigheid. 
Alhoewel beide insulienweerstandigheid en NAFLD bekend is om by te dra tot hartafwykings 
in vetsug, is dit nie duidelik wat eerste ontwikkel nie. Met die stygende las van vetsugverwante 
hartsiektes is dit noodsaaklik om die risikofaktore wat betrokke is om hartversaking beter te 
verstaan en in sodoende, beter te behandel of te voorkom. 
 
Doelstelling: Om die volgorde van aanvang van NAFLD en insulienweerstandigheid in 
vetsugverwante hartafwykings te ondersoek. 
 
Metodes: Ses tot vyftien week-oue manlike leptien-reseptor-gebrekkige (Leprdb/db) -muise en 
hul maer beheerkontroles (Leprdb/+) is weekliks gemonitor om bloedglukose en liggaamsgewig 
te meet. Hartfunksie is weekliks vasgestel met behulp van TDI-ekkokardiografie, waarna 8 
diere per groep beëindig is. Serum is ingesamel om lipogram en lewer ensieme te meet, terwyl 
spier-, lewer- en hartweefsel gebruik is om insulienweerstandigheid, NAFLD en hartafwykings 
onderskeidelik te ondersoek. 
 
Resultate: Die data wat verkry is, het getoon dat Leprdb/db-muise hoёr gewig (31,75 g ± 0,71 
vs. 20,50 g ± 0,55, p <0,001) en totale cholesterol (3,90 mmol / L ± 0,14 teenoor 1,90 mmol / 
L ± 0,04, p <0,001) gehad het teen 6 weke oud. Serum AST/ALT-verhouding (0.76 ± 0.07) het 
lewer lipiedakkumulasie teen 7 weke aangedui en histologiese analise het die 
teenwoordigheid van NAFLD op hierdie tydstip bevestig, sowel as die ontwikkelling daarvan 
in erns met ouderdom. Gene-ekspressie-analise in die lewer het 'n toename in lipogene gene 
FASN (1.16 ± 0.18 vs. 0.25 ± 0.05, p <0.01) en SCD1 (1.03 ± 0.08 vs. 0.20 ± 0.05, p <0.001) 
teen 7 weke oud. Spierinsulienweerstand was nie teenwoordig by die aanvang van NAFLD 
nie, en ontwikkel ongeveer 10 weke oud, soos bevestig deur 'n afname in pPI3K- en pAKT-
proteïenuitdrukking (0.17 ± 0.03 vs 0.10 ± 0.01, p <0.01 and 0.23 ± 0.06 vs 0.12 ± 0,03, p 
<0,05, onderskeidelik). Gene-ekspressie-analise bevestig 'n toename in oksidatiewe stres 
NOX4 (1.23 ± 0.30 vs. 0.77 ± 0.09, p <0.05), inflammasie NFκB (1,68 ± 0.09 vs. 0.69 ± 0.04, 
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p <0.001) en apoptose CASP3 (1.42 ± 0.10 vs. 1.06 ± 0.06, p <0.05) in die hart van Leprdb/db 
muise teen 10 weke. 
 
Gevolgtrekking: Lewer steatosis kom voor spier insulien weerstandigheid voor in 'n genetiese 
model van vetsug, en dra waarskynlik by tot die ontwikkeling van insulien weerstand en 
miokardiale afwykings. 
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Chapter 1: Literature Review 
 
 Non-communicable diseases 
Non-communicable diseases (NCDs) are chronic, non-transmissible and slow-progressing 
conditions that include cardiovascular disease (CVD), respiratory disease, cancer and 
diabetes. The World Health Organization (WHO) has identified smoking of tobacco products, 
excessive alcohol consumption, lack of physical activity and an unhealthy diet as the main risk 
factors associated with the development of NCDs (WHO, 2017). While these risk factors are 
largely modifiable, NCDs have continued to increase in prevalence and are now responsible 
for 71% of all global deaths, far exceeding the number of deaths caused by communicable 
diseases (Figure 1.1). Of the four main NCDs, CVD is the most prevalent, comprising 44% of 
NCD cases and causing 17.9 million deaths in 2016 (WHO, 2018). 
 
Figure 1.1: Global causes of death. Causes of death worldwide as a % of total deaths among all ages 
and genders in 2016. Adapted from World Health Organization noncommunicable diseases country 
profiles, 2018  
 
 Cardiovascular disease 
Cardiovascular disease is a term that encompasses a wide range of conditions involving 
narrowed or blocked heart vessels that can result in heart failure. Of these conditions, 
atherosclerotic heart disease, such as coronary artery disease and stroke, are widely studied 
and relatively well-understood (Mandviwala, et al., 2016; Leong, et al., 2017). Additionally, in 
1972 Rubler, et al. identified a heart condition that results in structural and functional changes 
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to the myocardium, in the absence of coronary artery disease or hypertension, as a 
consequence of metabolic perturbations such as obesity, insulin resistance, and type 2 
diabetes mellitus (T2DM). These structural and functional changes, further referred to as 
cardiac dysfunction, develop slowly and are aggravated due to increased gluco- and 
lipotoxicity induced by the hyperglycaemic and hyperlipidaemic state. It has been proposed 
that a shift in substrate preference, due to metabolic inflexibility, plays a central role in the 
pathophysiology of cardiac dysfunction. This alteration in energy metabolism markedly 
increases oxidative stress, hypertrophy, and interstitial fibrosis, resulting in myocardial 
structural modifications with impaired cardiac relaxation and reduced left ventricular ejection 
fraction (LVEF).  
 
These subtle changes are initially asymptomatic and cannot be detected, except with the use 
of image modalities such as Tissue Doppler Imaging (TDI) echocardiography or Speckle 
Tracking echocardiography (Goland, et al., 2006; Stevanovic & Dekleva, 2018). However, 
early intervention for cardiac dysfunction is difficult, as it only becomes clinically evident late 
in disease progression when the damage is irreversible (Loncarevic, et al., 2016; Borghetti, et 
al., 2018). Encouragingly, most CVDs, including cardiac dysfunction, can be prevented by 
addressing the preceding risk factors (WHO, 2017) and as such, it is important to understand 
the pathophysiology of these underlying conditions. 
 
 Metabolic syndrome 
Metabolic syndrome (MetS) is a term used to describe a cluster of metabolic abnormalities 
that increases an individual’s risk of developing CVD (Reaven, 2011; Rask-Madsen & Kahn, 
2012). The exact characterization of MetS differs between countries; however, in 2001 the 
National Cholesterol Education Program (NCEP) introduced a simple yet reliable clinical 
definition. According to this definition, MetS is characterized by five risk factors, including; 
abdominal obesity (waist circumference > 88 cm in women and > 102 cm in men), impaired 
fasting blood glucose (5.6 - 6.9 mmol/L), increased triglycerides (> 1.7 mmol/L), reduced high-
density lipoprotein (HDL) (< 1.3 mmol/L in women and < 1 mmol/L in men), and chronic 
hypertension (systolic blood pressure > 130 mmHg and diastolic blood pressure > 85 mmHg) 
(Paschos & Paletas, 2009). The occurrence of one of these conditions increases an 
individual’s risk of developing CVD, while the co-occurrence of three or more conditions results 
in a diagnosis of MetS and infers a significantly elevated risk of CVD (Gurka, et al., 2018). 
Stellenbosch University  https://scholar.sun.ac.za
  
3 
 
More recently, non-alcoholic fatty liver disease (NAFLD) has also been recognized as part of 
MetS, as individuals with NAFLD exhibit a worsened cardiometabolic phenotype, 
accompanied by impaired systolic and diastolic function (Fotbolcu, et al., 2010; Karabay, et 
al., 2014). Non-alcoholic fatty liver disease can be defined as a condition in which excess 
lipids are accumulated in more than 5% of the liver, in the absence of excess alcohol 
consumption (Birkenfeld & Shulman, 2014). Not only is NAFLD the most common liver disease 
in the Western world (Ahmed, 2015), but it is also closely associated with obesity, with an 
estimated 80 - 90% of obese patients suffering from intrahepatic lipid accumulation (Gaggini, 
et al., 2013). 
 
 Obesity 
One of the most prominent conditions associated with MetS is visceral obesity, also known as 
central or abdominal obesity. Visceral obesity refers to the accumulation of excessive fat 
stores within and around the abdominal cavity, including fat stores around internal organs 
such as the heart, liver, and pancreas. According to the WHO, an individual with a body mass 
index (BMI) > 25 kg/m2 is classified as overweight, while an individual with a BMI > 30 kg/m2 
is considered obese. Obesity has become a global epidemic and it is estimated that 39% of 
adults are overweight and 13% are obese, while in South Africa, 53.8% of adults are 
overweight and 28.3% are obese (WHO, 2018). Furthermore, it is estimated that there will be 
a 33% increase in obesity worldwide by 2030 (Finkelstein, et al., 2012). 
 
Studies have shown that obese individuals have increased lipid stores. However, lipid stores 
within the body are not inherently pathological, as a small amount of fat (3 - 5% in men and 
12 - 15% in women) is required for normal body function. Lipids such as triglycerides and 
cholesterol are stored in specialized fat cells called adipocytes and form a key component of 
adipose tissue, which helps to maintain hormonal balance while supporting thermoregulation 
and energy homeostasis (Landrier, et al., 2012). Obesity is often associated with excess 
dietary intake of energy in the form of high-fat high-sugar meals. In times of excess energy 
availability, glucose can be stored as glycogen in the liver, or substrates can be converted to 
triglycerides and stored in adipose tissue. In times of high energy demand, triglyceride stores 
are broken down by lipolysis and transported to peripheral tissues where they are oxidized 
and used as a source of energy (Turnbull, et al., 2016). Thus, the balance between lipogenesis 
and lipolysis is crucial and dysregulation thereof may lead to lipid accumulation. 
There are two main types of adipose tissue, white adipose tissue (WAT) and brown adipose 
tissue (BAT). Where BAT is associated with energy expenditure, the main function of WAT is 
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to store excess energy as triglycerides. In obesity, increased triglyceride storage in adipose 
tissue results in an increase in adipocyte size (hypertrophy) and number (hyperplasia) 
(Lessard, et al., 2014). Of the two types, WAT compared to BAT has been more closely linked 
to the disruption of lipid metabolism, altered adipokine secretion, inflammation and 
subsequent insulin resistance. In a population-based study using obese women, Michaud, et 
al. (2016) found a strong positive correlation between enlarged adipocytes (increased WAT) 
in both visceral and subcutaneous adipose tissues (VAT and SAT), and impaired insulin 
sensitivity, demonstrating that a link exists between excess fat deposition and deleterious 
metabolic alterations.  
 
1.4.1 Adipose tissue dysfunction 
Adipocytes and pre-adipocytes are embedded in the extracellular matrix (ECM) of adipose 
tissue, which also contains resident tissue macrophages that assist in the mediation of 
adipokine secretion as well as the generation and degradation of ECM. During obesity, 
adipose tissue expansion via adipocyte hypertrophy, can disrupt these functions and result in 
chronic, low-grade inflammation, insulin resistance and ectopic fat accumulation (Figure 1.2). 
Adipocyte hypertrophy causes adipose tissue macrophages to produce mediators such as 
tissue growth factor beta (TGF-β) and platelet derived growth factor (PDGF), which attracts 
and activates fibroblasts. Fibroblasts initiate fibrogenesis, which alters the expandability of 
adipose tissue and causes fat to be stored ectopically. According to findings by Lessard, et al. 
(2014), loss of expandability in SAT leads to visceral fat storage, hypertrophy and multiple 
metabolic consequences such as insulin resistance and NAFLD. Ectopic fat accumulation in 
organs such as the liver may therefore interfere with cellular function and hence the 
development of insulin resistance. 
 
Adipocyte hypertrophy also alters adipokine secretion, causing a decrease in the secretion of 
adiponectin, an important adipokine with a role in obesity-induced insulin resistance (Kim, et 
al., 2018). Simultaneously, there is an increase in cytokine secretion, causing macrophages 
from the circulation to be recruited and activated. Macrophages can either be “classically” 
activated, taking on a pro-inflammatory M1 phenotype, or they can be “alternatively” activated 
to take on an anti-inflammatory M2 phenotype. In the case of adipose tissue expansion by 
hypertrophy, macrophages undergo classical activation, further increasing cytokine release 
and promoting inflammatory signalling (Luo, et al., 2017), which can lead to local and systemic 
insulin resistance (Figure 1.3).  
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Figure 1.2: Adipose tissue dysfunction in obesity. Storage of excess energy in the form of 
triglycerides within adipose tissue can cause adipocyte hypertrophy, leading to inflammation, altered 
adipokine secretion and remodelling of the extracellular matrix (ECM), culminating in insulin resistance 
and ectopic fat accumulation. Illustrations created using www.somersault1824.com. 
 
One of the first, and possibly the most well-studied cytokine in relation to obesity-induced 
inflammation is tumour necrosis factor alpha (TNFα). Under normal conditions, inhibitor of 
kappa B alpha (IκBα) sequesters nuclear factor kappa B (NFκB) in the cytosol, inhibiting its 
translocation. However, TNFα signalling causes phosphorylation of inhibitor of kappa B kinase 
beta (IKKβ), which then causes IκBα to degrade and release NFκB. The liberated NFκB is 
then able to translocate to the nucleus and initiate transcription of pro-inflammatory genes 
(Zhao, et al., 2015). Furthermore, FFAs serve as ligands for the toll-like receptor 4 (TLR4) 
complex, which activates the classical inflammatory response and promotes recruitment and 
accumulation of macrophages in the adipose tissue (Bai & Sun, 2015). These macrophages 
produce large amounts of pro-inflammatory mediators such as TNFα and interleukin 6 (IL6) 
that causes adipose tissue insulin resistance. 
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Figure 1.3: Molecular mechanisms of obesity-induced inflammation and insulin resistance. A) 
Obesity causes the activation of an immune response and release of pro-inflammatory cytokines such 
as tumour necrosis factor alpha (TNFα) and interleukin 6 (IL6), initiating transcription of inflammatory 
genes. B) Under normal conditions (blue arrows) insulin stimulates the translocation of glucose 
transporter 4 (GLUT4) and uptake of glucose into the cell, while inhibiting lipolysis and 
gluconeogenesis. In an obese state (red arrows) inflammation and increased free fatty acids disrupt the 
insulin signalling cascade and inhibit GLUT4 translocation. Illustrations created using 
www.somersault1824.com. 
 
In addition to storage of excess energy, adipose tissue fulfils an important endocrine function. 
Therefore, adipose tissue dysfunction is not dependent entirely on the amount of fat 
deposition, but also on the altered release of adipokines. Fonseca (2003) showed that 
improving adipocyte function with a peroxisome proliferator activator γ (PPARγ) agonist 
improved insulin sensitivity in humans, despite significant gains in fat mass. As an endocrine 
organ, dysfunction of adipose tissue can result in the activation of a pro-inflammatory 
response with major consequences for pancreatic β-cell failure, hepatotoxicity, muscle insulin 
resistance and cardiac dysfunction. This pro-inflammatory state promotes insulin resistance 
and drives MetS, increasing the risk of heart failure. 
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 Insulin resistance 
Insulin is a hormone that plays a vital role in energy homeostasis and metabolism. It is 
synthesized and released by pancreatic β-cells in response to an elevation in blood glucose 
levels. This increase in glucose-stimulated insulin secretion will allow for uptake and 
subsequent use or storage of glucose in peripheral tissue. In an insulin resistant state, insulin 
is hyper-secreted which results in the inability of peripheral tissue to utilize glucose effectively, 
leading to hyperinsulinaemia and hyperglycaemia (Lebovitz, 2001). Furthermore, insulin 
resistance promotes lipogenesis and causes a positive feedback loop which further 
exacerbates obesity. Chronic hyperglycaemia and hyperinsulinaemia caused by insulin 
resistance can also lead to pancreatic β-cell failure and T2DM. 
 
Under normal physiological conditions, the insulin signalling pathway (Figure 1.3 B) is 
activated when insulin binds to the insulin receptor on the cell membrane, leading to 
phosphorylation of insulin receptor substrate 1 at Tyr618 (IRS1Tyr618). A signalling cascade is 
then initiated by which the phosphorylation of phosphoinositide-dependent protein kinase at 
Tyr688 (PI3KTyr688) leads to the phosphorylation of protein kinase B at Ser473 (AKTSer473). This 
in turn leads to the translocation of glucose transporter 4 (GLUT4) from the cytosol to the cell 
membrane, allowing for the active transport of glucose into the cell from the circulation 
(Brewer, et al., 2014). Insulin resistance occurs when this pathway is inhibited and can be 
caused by a number of obesity-related factors. 
 
Numerous pre-clinical and clinical studies have implicated obesity-induced chronic low-grade 
inflammation in the development of insulin resistance (Lee & Lee, 2014; Straub, 2014). As 
previously mentioned, obesity-induced inflammation is caused by the infiltration of 
macrophages to the adipose tissue and the increased expression of pro-inflammatory 
cytokines such as TNFα (Ye, 2013). Acting through TNFα receptor 1 (TNFR1), TNFα inhibits 
IRS1 in the insulin signalling pathway, thereby rendering the cell less responsive to insulin by 
inhibiting GLUT4 translocation. This has been shown by Hotamisligil, et al. (1994), where 
TNFα inhibited insulin-stimulated tyrosine phosphorylation of IRS1 in skeletal muscle, while 
neutralization of TNFα restored insulin sensitivity to a level comparable to control animals. In 
addition to inhibiting IRS1, TNFα activates inflammatory pathways within the cell, including 
the IKKβ/NFκB pathway as well as the jun-N-terminal kinase 1 (JNK1) pathway (Ye, 2013). 
The activity of IKKβ and JNK1 inhibit insulin signalling by phosphorylating IRS1 at Ser307, 
thereby preventing phosphorylation at tyrosine residues, which is required for insulin 
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sensitivity. TNFα also activates PPARγ, a nuclear receptor that drives lipid synthesis and fat 
storage in cells, further increasing insulin resistance (Zhang, et al., 2014). 
 
Another mechanism by which obesity may lead to the development of insulin resistance is by 
increasing plasma FFAs. Free fatty acids enter the cell via the cluster of differentiation 36 
(CD36) receptor and are metabolised, increasing long-chain fatty acid (LCFA) intermediates 
such as diacyl glycerol (DAG) and ceramides. These lipid intermediates bind and recruit 
protein kinase C theta (PKCθ) to the plasma membrane where it is activated and in turn 
activates IKKβ and JNK and proceeds to inhibit phosphorylation of IRS1Ser307 (Szendroedi, et 
al., 2014). 
 
1.5.1 Insulin resistance and cardiac dysfunction 
Insulin resistance is a hallmark of T2DM, with T2DM being characterised by complete loss of 
pancreatic β-cell function. Both insulin resistance and T2DM are risk factors for the 
development of cardiac dysfunction through various pathways (Figure 1.4). Under normal 
physiological conditions the heart is metabolically flexible as it is able to utilize both fatty acids 
and glucose as a substrate/energy source (Jia, et al., 2017). However, in the case of 
myocardial insulin resistance GLUT4 is not translocated, while the translocation of CD36 is 
unaffected (Battiprolu, et al., 2013). This results in reduced glucose uptake into the heart with 
maintained fatty acid uptake, subsequently causing a shift in substrate preference to favour 
almost exclusive utilization of fatty acids  (Schwenk, et al., 2008). Fatty acid metabolism in the 
heart is oxygen inefficient and renders the heart more susceptible to ischemic damage 
(Chowdhry, et al., 2007). Additionally, recent studies suggest that these metabolic changes 
initiate several molecular events in the heart that lead to morphological and mechanical 
changes, and ultimately cardiac dysfunction (Ghosh & Katare, 2018).  
The shift in substrate preference and chronic hyperglycaemia is accompanied by increased 
ROS production in the mitochondria of the obese heart. This causes increased expression of 
pro-inflammatory cytokines, thereby contributing to the suppression of insulin signalling and 
activating apoptosis responses in the myocyte (Li, et al., 2012). During chronic 
hyperglycaemia, caused by insulin resistance, reducing sugars can bind to proteins or lipids 
to form advanced glycation end products (AGEs) (Zieman & Kass, 2004). This plays a role in 
the crosslinking of collagen fibres in the myocardium, promoting fibrosis (Aronson, 2003). 
Receptors of AGEs (RAGE) are also activated by oxidative stress, a result of the pro-
inflammatory phenotype associated with obesity and diabetes, and in turn activates the NFκB 
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signalling pathway, which exacerbates insulin resistance and promotes fibrosis (Aragno, et 
al., 2006). Diabetes also causes the modification of Ca2+/calmodulin dependent protein kinase 
2 (CAMK2), which connects with sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and is 
related to the pathophysiology of contractile dysfunction, though the exact mechanism is not 
known (Liu, et al., 2016). 
 
Figure 1.4: Insulin resistance leads to cardiac dysfunction. Insulin resistance can lead to cardiac 
dysfunction by decreasing cardiac efficiency and by causing fibrosis and contractile dysfunction. 
Illustrations created using www.somersault1824.com. 
 
In addition to its manifold role in the development of cardiac dysfunction, insulin resistance is 
also known to occur in patients with NAFLD (Utzschneider & Kahn, 2006). Nevertheless, each 
condition can occur in the absence of the other, and each is known as an independent risk 
factor for the development of cardiometabolic aberrations (Mantovani, et al., 2015; Sirbu, et 
al., 2016). This raises the question of what exactly the mechanisms are by which the co-
occurrence of insulin resistance and NAFLD leads to cardiac dysfunction. 
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 NAFLD 
Non-alcoholic fatty liver disease is the most common liver disease in the Western world 
(Ahmed, 2015) and is closely associated with obesity, with an estimated prevalence of 80-
90% in obese patients. Several studies (Han & Lee, 2017; Ter Horst & Serlie, 2017) reported 
on NAFLD as the hepatic component of the metabolic syndrome, as intrahepatic lipid 
accumulation and inflammation has been identified as an independent risk factor for the 
development of CVD (Han & Lee, 2017). The disease itself develops in stages, starting with 
benign lipid accumulation and ranging to severe steatosis accompanied by inflammation and 
fibrosis (Figure 1.5). 
 
 
Figure 1.5: Progression of NAFLD. Intrahepatic lipid accumulation in non-alcoholic fatty liver disease 
(NAFLD) can progress from microvesicular changes to macrovesicular changes, the latter being 
accompanied by nuclear displacement and hepatocellular hypertrophy. Illustrations created using 
www.somersault1824.com. 
 
The earliest stage of NAFLD presents as simple steatosis, characterized by evidence of fat 
accumulation in more than 5% of the liver, beyond normal, healthy hepatic lipid content and 
in the absence of excessive alcohol consumption (Birkenfeld & Shulman, 2014). 
Approximately 37% of NAFLD cases undergo histopathological progression to non-alcoholic 
steatohepatitis (NASH), which can be identified when the excess lipid content is accompanied 
by inflammation and mild fibrosis. From there, up to 20% of cases progress to hepatic 
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cirrhosis, hepatocellular carcinoma, and end-stage liver failure (Bugianesi, et al., 2005; Liang, 
et al., 2014). 
 
Hepatic lipid accumulation occurs due to an imbalance between lipid influx and lipid removal 
(Figure 1.6), leading to lipotoxicity and hepatic injury (Lonardo, et al., 2015). Several factors 
can contribute to this imbalance, including excessive FFA import and storage, increased de 
novo lipogenesis, impaired lipolysis by β-oxidation, and diminished export of FFA from liver 
(Trevaskis, et al., 2012; Yamada, et al., 2017)  
 
Figure 1.6: The two-fold causality of intrahepatic lipid accumulation. Lipid accumulation in the liver 
can be caused by insulin resistance, leading to hyperinsulinaemia and subsequent activation of sterol 
regulatory element binding factor 1 (SREBF1), causing increased de novo lipogenesis and decreased 
fatty acid β-oxidation. Simultaneously, increased free fatty acid (FFA), spill-over from adipose tissue 
due to obesity, can be taken up into the liver via the cluster of differentiation 36 (CD36) receptor, where 
it accumulates as the rate of uptake is greater than the rate of disposal by β-oxidation. Illustrations 
created using www.somersault1824.com. 
 
In the obese state, hepatic insulin resistance may develop due to pro-inflammatory signalling 
from the adipose tissue. Hyperinsulinaemia due to insulin resistance acts via sterol-regulatory 
element-binding factor 1 (SREBF1) to produce excess lipogenic enzymes such as fatty acid 
synthase (FASN) and stearoyl-coenzyme A desaturase 1 (SCD1) (Sobel, et al., 2017). These 
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enzymes drive de novo lipogenesis by facilitating the conversion of glucose to triglycerides 
and can lead to lipid accumulation in the liver (Cohen, et al., 2011). This was shown by Repa, 
et al. (2014), who found that induction of SREBF1 stimulated lipogenesis and promoted 
hepatic hypertriglyceridaemia. Carnitine palmitoyl transferase 1 (CPT1) is an essential 
enzyme that transports fatty acids to the mitochondria for β-oxidation. However, Malonyl 
coenzyme A (Malonyl-CoA), an intermediate of triglyceride conversion, acts as an inhibitor of 
CPT1, reducing lipid clearance.  
 
Obesity can also cause NAFLD independent of insulin resistance, as adipose tissue 
dysfunction results in FFA spill-over into circulation. These excess FFA are transported to the 
peripheral tissue such as the liver, where they are taken up via CD36 and stored within 
hepatocytes. Free fatty acids in circulation can also activate TLR4 in the liver and 
consequently inhibits AMPK signalling and β-oxidation (Viollet, et al., 2010), further disrupting 
the balance and promoting intrahepatic lipid accumulation. 
 
1.6.1 NAFLD and cardiac dysfunction 
As mentioned previously, NAFLD is also a known risk factor for cardiac dysfunction 
(Mantovani, et al., 2015) (Figure 1.7). Visceral adipose tissue and intrahepatic fat cause a 
systemic release of pathogenic mediators, such as C-reactive protein (CRP), IL6, TNFα, and 
other inflammatory cytokines (Mantovani, et al., 2015), exacerbating insulin resistance and 
conferring a 2- to 4-fold increased risk for the development of T2DM (Han & Lee, 2017). By 
enhancing the dysfunctional metabolic phenotype in such a way, NAFLD may contribute to 
cardiac dysfunction, as described under insulin resistance-induced cardiac dysfunction. 
Interestingly, an independent association has also been found between NAFLD and left 
ventricular diastolic dysfunction (LVDD) in type 2 diabetic patients, most probably additive to 
the myocardial defects already present in T2DM (Bonapace, et al., 2012). This is similar to 
findings by Karabay, et al. (2014), where patients with NAFLD showed evidence of subclinical 
myocardial dysfunction. 
 
A positive relationship has been reported between the histological severity of NAFLD and 
certain features of CVD, including LVDD (Sookoian, et al., 2011). In the case of insulin 
resistance there is greater uptake of fatty acids into the cardiomyocyte, as described 
previously. In cases where myocardial lipid uptake exceeds FA oxidative metabolism, 
myocardial lipid accumulation can occur. The accumulation of lipid metabolism intermediates 
can then cause oxidative stress and apoptosis (Schulze, 2009). In the hyperlipidaemic state, 
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there is also increased activation of TGF-β (Hong, et al., 2016) which in turn activates 
connective tissue growth factor (CTGF) (Bonniaud_2004). In a study by Chen, et al. (2000), 
isolated human and rat cardiomyocytes were treated with TGF-β and showed consistently 
increased expression of CTGF. This was accompanied by increased expression of fibronectin, 
an indication of ECM remodelling, as well as inter-myofibril and perivascular fibrosis  (Chen, 
et al., 2000). 
 
 
Figure 1.7: NAFLD causes Myocardial Dysfunction. Non-alcoholic fatty liver disease (NAFLD) can 
lead to myocardial dysfunction via various pathways, including exacerbation of insulin resistance, 
dyslipidaemia, and oxidative stress. Illustrations created using www.somersault1824.com 
.  
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 Connecting the underlying pathologies 
Both insulin resistance and NAFLD have been identified as independent risk factors for 
cardiac dysfunction (Kumar, et al., 2016). Insulin resistance has been shown to play a role in 
myocardial dysfunction through various mechanisms, including hyperglycaemia, glucotoxicity, 
ROS, and inflammation, eventually causing cardiac damage and remodelling (Ghosh & 
Katare, 2018). Similarly, numerous studies suggest that NAFLD is not just a co-occurrence, 
but that it can contribute to the pathogenesis of cardiac dysfunction by causing lipotoxicity and 
contributing to the pathological phenotype (Mantovani, et al., 2015). At the same time, there 
is a close association between insulin resistance and NAFLD, with insulin resistance being 
well-known for causing NAFLD. However, whether hepatic fat accumulation can cause insulin 
resistance remains a topic of debate (Gruben, et al., 2014; Gastaldelli, 2017). Since a better 
understanding of the different diseases can allow for better treatment or prevention, it may 
prove useful to investigate the causal role of NAFLD in insulin resistance, and to delineate the 
order of onset leading up to the development of cardiac dysfunction.  
 
1.7.1 Evidence that insulin resistance causes NAFLD 
Insulin resistance is a known cause of hepatic lipid accumulation. Under physiological 
conditions, insulin inhibits hepatic gluconeogenesis and promotes hepatic lipogenesis. 
However, during insulin resistance inhibition of gluconeogenesis is halted, while lipogenesis 
remains activated, likely due to the activation of SREBF1 by hyperinsulinaemia, resulting in 
activation of lipogenic genes such as FASN and SCD1. This results in excess de novo 
lipogenesis and the development of NAFLD and has been reported in several studies, as 
discussed below and summarised in table 1.1. 
 
In a study by Bugiuanesi, et al. (2005) the authors observed that NAFLD patients had marked 
peripheral insulin resistance and impaired lipid oxidation, leading to the conclusion that excess 
non-esterified fatty acids (NEFA) flux from the insulin resistant adipose tissue caused ectopic 
fat accumulation and the observed hepatic steatosis. This was also shown in a population-
based longitudinal study where Zheng, et al. (2018) showed that insulin resistant individuals 
with increased circulating triglycerides and glucose had a significantly higher rate of incident 
NAFLD over the 9-year follow-up period. 
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Table 1.1: Summary of literature: insulin resistance as a cause of NAFLD 
Model Key findings Reference 
Human Increased NEFA flux due to adipose tissue insulin resistance could cause NAFLD (Bugianesi, et al., 2005) 
Human 
Patients with increased circulating triglycerides, glucose and insulin resistance 
had higher incident NAFLD on 9-year follow-up 
(Zheng, et al., 2018) 
Human Alleviating insulin resistance with rosiglitazone treatment also improved NAFLD (Neuschwander-tetri, et al., 2003) 
Mouse 
(db/db) 
Restoring the insulin signalling pathway could reverse NAFLD (Xu, et al., 2018) 
Table legend: db/db: leptin receptor-deficient, NEFA: non-esterified fatty acids, NAFLD, non-alcoholic fatty liver disease,  
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In support of insulin resistance as the cause of NAFLD, Neuschwander-tetri, et al. (2003) 
showed that improving insulin sensitivity with rosiglitazone also ameliorated NAFLD. Similarly, 
Xu, et al. (2018) showed that improvement of insulin sensitivity in a leptin receptor-deficient 
db/db (Leprdb/db) mouse model by regulation of the IRS/PI3K/AKT signalling pathway could 
improve hepatic steatosis, showing the involvement of the insulin signalling pathway in the 
disease pathophysiology of NAFLD. 
It is worth noting that most studies that investigated insulin resistance and NAFLD use obese 
humans or animal models. However, obesity is a known cause of insulin resistance, 
independent of the absence or presence of NAFLD possibly implicating obesity as a 
confounding factor when studying the causal role of NAFLD in insulin resistance (Pamir, et 
al., 2009; Schattenberg & Galle, 2010). Thus, to more clearly identify the effect of NAFLD on 
insulin resistance, without weight as a confounding factor, studies of “genetic” NAFLD may 
prove useful. 
 
In a study where NAFLD was genetically induced by liver X receptor knock-out (LXR-KO), 
Grefhorst, et al. (2005) showed that increased activation of SREBF1 in the liver led to 
subsequent hepatic steatosis. However, this did not affect hepatic or peripheral insulin 
sensitivity. Similarly, a study by Koonen, et al. (2007) found that hepatic overexpression of the 
fatty acid transporter CD36 using adenoviral gene delivery (ad.CD36) caused fat accumulation 
in the livers of genetically modified mice but did not lead to the development of insulin 
resistance. Patatin-like phospholipase domain-containing protein 2 (PNPLA2) is a lipase that 
plays an important role in the hydrolysis of triglycerides. By creating a PNPLA2 knock-out 
mouse model (PNPLA2-KO) Wu, et al. (2011) were able to study body-weight independent 
NAFLD. In this study, the authors observed that PNPLA2-KO mice developed marked hepatic 
steatosis, while insulin sensitivity remained comparable to that of controls. More recently, 
Franko, et al. (2018), showed that humans that carried a specific single nucleotide 
polymorphism (SNP) in the PNPLA3 gene had fatty liver but maintained insulin sensitivity. In 
the same study it was observed that subjects that did not carry the SNP, but who had high 
liver fat, were insulin resistant. In further genetic studies, Amaro, et al. (2011) investigated 
subjects with familial hypobetalipoproteinaemia (FHBL), who had a defect in the export of 
triglycerides from the liver and subsequent intrahepatic lipid accumulation. In this study, FHBL 
patients had evident NAFLD, but maintained hepatic and peripheral insulin sensitivity. These 
studies are summarised in table 1.2 and provide evidence that NAFLD can develop 
independent of insulin resistance, and that the presence of NAFLD does not irrefutably lead 
to the development of insulin resistance. 
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Table 1.2: Summary of literature: evidence that NAFLD does not cause insulin resistance 
Model Key findings Author 
Mouse 
(ob/ob) 
SREBF1-induced hepatic steatosis did not affect insulin sensitivity. (Grefhorst, et al., 2005) 
Mouse 
(Ad.CD36) 
Hepatic overexpression of CD36 resulted in fat accumulation, but not insulin 
resistance. 
(Koonen, et al., 2007) 
Mouse 
(PNPLA-KO) 
PNPLA-KO mice had marked steatosis, but maintained insulin sensitivity (Wu, et al., 2011) 
Human, 
FHBL 
Steatosis is dissociated from insulin resistance in FHBL, which suggests that 
increased intrahepatic triglyceride content is a marker, not a cause, of metabolic 
dysfunction 
(Amaro, et al., 2011) 
Human, 
PNPLA3 SNP 
SNP with high liver fat maintained insulin sensitivity while wild type subjects with 
high liver fat were insulin resistant 
(Franko, et al., 2018) 
Table legend: ob/ob: leptin-deficient, SREBF: Sterol regulatory element binding factor 1, CD36: cluster of differentiation 36, PNPLA: Patatin-like phospholipase 
domain-containing protein, FHBL: familial hypobetalipoproteinaemia, SNP: single nucleotide polymorphism 
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1.7.2 Evidence that NAFLD causes insulin resistance 
While insulin resistance is frequently considered the cause of intrahepatic lipid accumulation 
(Sanyal, et al., 2001) evidence suggests that NAFLD can develop prior to and be a cause of 
insulin resistance  (Yamada, et al., 2010; Singh, et al., 2015; Han & Lee, 2017). Excess 
triglycerides may be present in circulation independent of adipose tissue insulin resistance 
and are still taken up and stored as fat in the liver. Similarly, increased de novo lipogenesis 
may be attributed to the increase in uptake and conversion of glucose to fat. Interestingly, 
NAFLD in patients without insulin resistance is characterized by more severe liver damage, 
as evidenced by higher levels of aspartate transaminase (AST) and alanine transaminase 
(ALT) (Singh, et al., 2015). Thus, it may be that the lipid accumulation and inflammation 
associated with the later stages of NAFLD leads to insulin resistance and subsequent T2DM. 
Studies that provide evidence of the causal role of NAFLD in insulin resistance are discussed 
below and summarised in table 1.3. 
 
The role of NAFLD-induced inflammation in the development of insulin resistance was 
displayed by Cai, et al. (2006), where hepatic lipid accumulation caused NFκB activation and 
downstream cytokine production, leading to both hepatic and systemic insulin resistance. 
Similarly, Korenblat, et al. (2008) observed that the progressive increase in hepatic triglyceride 
content is associated with the development of insulin resistance in the liver as well as skeletal 
muscle and adipose tissue in humans, and therefore state that NAFLD should be considered 
as a cause of insulin resistance. In a study on non-diabetic humans, Yamada, et al. (2009) 
showed that fatty liver is an independent risk factor for impaired fasting glucose and the later 
development of T2DM, independent of body weight. Additionally, Lomanco, et al. (2012) 
showed that the degree of insulin resistance increased proportionally with NAFLD severity 
and that insulin resistance was worse in obese patients with NAFLD compared to those 
without NAFLD, suggesting that insulin resistance is at least somehow affected by NAFLD. 
Stellenbosch University  https://scholar.sun.ac.za
  
19 
 
 
 
Table 1.3: Summary of literature: evidence that NAFLD is a cause of insulin resistance 
Model Key findings Author 
Mouse IKKβ 
over-expression 
Hepatic lipid accumulation caused inflammation and insulin resistance. (Cai, et al., 2006) 
Human 
Increases in hepatic triglyceride content are associated with progressive 
development of insulin resistance. 
(Korenblat, et al., 2009) 
Human Fatty liver is an independent risk factor for impaired fasting glucose (Yamada, et al., 2010) 
Human 
Insulin resistance was worse in obese patients with NAFLD than obese patients 
without NAFLD 
(Lomonaco, et al., 2012) 
Table legend: IKKβ: Inhibitor of kappa B kinase beta, NAFLD, non-alcoholic fatty liver disease 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
  
20 
 
 Leprdb/db mice as a model organism to study NAFLD/IR 
Murine models, due to their physiological similarity to humans and relative ease with which 
their condition can be manipulated, are widely used as a model organism in the research of 
metabolic diseases (Alquier & Poitout, 2018). Several murine models exist for the study of 
metabolic disorders, including those where obesity and diabetes are induced by feeding 
animals various combinations of a high-fat-high-sugar (HFHS) diet. Other models exist where 
the animal has been genetically manipulated to be predisposed to the development of obesity 
and diabetes; these include the leptin-deficient ob/ob (Leprob/ob) mouse and the Leprdb/db 
mouse. The later model is popular in the study of obesity, dyslipidaemia, T2DM, NAFLD, and 
diabetic cardiomyopathy (Kobayashi, et al., 2000; Dludla, et al., 2017; Yin, et al., 2017; 
Guilbaud, et al., 2018). Due to the deficiency in leptin signalling, db/db mice become 
hyperphagic and develop obesity within four- to six-weeks when fed standard laboratory chow. 
Kobayashi et al. (2000) show that by six-weeks of age, these mice develop hyperlipidaemia 
that is comparable to that seen in obese humans, and that this is accompanied by 
hyperglycaemia and hyperinsulinaemia. Similarly, when comparing a db/db mouse model to 
two models of diet-induced obesity, Guilbaud et al. (2018) found that db/db mice became 
obese earlier than the diet-induced models, and also exhibited more severe hyperglycaemia 
and glucose intolerance. They thus conclude that the db/db model was more representative 
of human T2DM than a diet-induced model of obesity. While studying the development of 
NAFLD in db/db mice, Yin et al. (2017) found that this model had increased expression of 
SREBF1, FASN and SCD1 when compared to heterozygous leptin receptor-deficient lean 
control (Leprdb/+) controls, corresponding with the human condition. Likewise, Dludla et al. 
(2017) have shown that db/db mice develop diabetes-related cardiac dysfunction around 16 
weeks of age, characterised by hyperglycaemia, hyperlipidaemia, and cardiac muscle 
remodelling. 
 
 Conclusion 
While findings with regards to the causal role of NAFLD in insulin resistance are apparently 
contradictory, Luukkonen, et al. (2016) suggests that the possible reason could be because 
of the different “origins” of NAFLD. They studied humans that were metabolically predisposed 
to NAFLD, due to diet and lifestyle, and compared them to humans who were genetically 
predisposed. Observations in this study showed that “metabolic” and “genetic” NAFLD had 
different pathologies in terms of the type of hepatic lipid content and the role that insulin 
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resistance played in the disease. In “genetic” NAFLD, it appears that an increase in lipid 
accumulation increases hepatic and systemic insulin resistance, while in “metabolic” NAFLD 
the combination of hyperinsulinaemia and hyperlipidaemia increases insulin resistance, which 
plays a causal role in the development of hepatic lipid accumulation (Gastaldelli, 2017). 
 
With the rising burden of obesity-related heart failure, it is becoming increasingly important to 
understand disease pathophysiology to allow for early identification and treatment of risk 
factors associated with CVD. It is evident that there are many links between NAFLD and insulin 
resistance, and the development of cardiac dysfunction. Thus, a better understanding these 
pathways may be helpful in reducing the burden of disease (Bonapace, et al., 2012). When 
studying the progression of MetS and cardiac dysfunction, different models may give valuable 
insight into the various circumstances under which the disease develops, possibly paving the 
way for more individualized treatment and risk prediction. 
 
Many review articles address the question of which came first, however much of the available 
research studies did not aim to investigate that specific relationship. Many studies indicate 
whether, but not “when”, subjects with insulin resistance also develop NAFLD. More 
experimental research is thus needed in this field. Specifically, longitudinal studies that track 
disease progression in different models. The purpose of the present study was to monitor mice 
that are known to develop both insulin resistance and NAFLD, and to establish when the onset 
of each event occurred. As both of these conditions are underlying causes of cardiac 
dysfunction, it also becomes imperative to monitor the state of the heart in such studies. 
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Aims of Investigation 
 
Aim:  
To investigate the order of onset of NAFLD and muscle insulin resistance, in a db/db mouse 
model, and the effect thereof on the development of cardiac dysfunction. 
 
Objectives: 
1. To determine the order of onset of NAFLD, insulin resistance and subsequent cardiac 
dysfunction in an obese db/db mouse model. 
2. To investigate the gene regulatory network involved in NAFLD, insulin resistance and 
myocardial dysfunction. 
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Chapter 2: Methodology 
 
 Study design 
Ethical clearance for the animal study was obtained from the South African Medical Research 
Council (SAMRC) Ethics Committee for Research on Animals (ECRA/05/15) and use of the 
tissues was approved by the University of Stellenbosch Research Ethics Committee for 
Animal Care and Use (Protocol #0301). Five-week old homozygous male leptin-receptor-
deficient (Leprdb/db) mice and their lean heterozygous littermates (Leprdb/+) were acclimated for 
one week to the experimental environment at the Primate Unit and Delft Animal Centre 
(PUDAC) of the SAMRC. The animal facility is environmentally controlled, with a 12-hour 
light/dark cycle and a temperature range of 23 °C - 25 °C, with relative humidity ~50%. All 
animals were given free access to standard mouse chow (Afresh Vention, Cape Town, RSA) 
and tap water. At 6 weeks of age, animals were divided into either a control (Leprdb/+) (n=32) 
or an experimental group (Leprdb/db) (n=32), based on obesity phenotype. Animals in each 
group were then randomized and further sub-divided into 4 subgroups (7-, 10-, 13- and 15-
weeks) with n=8 animals per group. Two animals were housed per cage grouping similar 
disease states together. Body weight, and fasting blood glucose levels were recorded weekly, 
while echocardiograph analysis was done for each time point 3 days prior to termination. 
 
2.1.1 Fasting blood glucose and insulin 
High fasting blood glucose and insulin levels are known to be associated with insulin 
resistance. For this reason, fasting blood glucose of both lean and obese animals was 
determined weekly (Dludla, et al., 2017). Briefly, animals were subjected to a 4-hour fast 
before blood was drawn by tail prick and analysed using a OneTouch Select® Glucose Meter 
(LifeScan Inc., California, USA). Insulin concentration in serum was determined using a 
Millipore, mouse insulin enzyme-linked immunosorbent assay (ELISA) kit (Merck, RSA). The 
homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by 
multiplying the fasting glucose concentration by the fasting insulin concentration and dividing 
by the set coefficient 22.5 (HOMA-IR = [fasting blood glucose (mmo/L) * fasting insulin 
(mmol/L)] / 22.5).  
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2.1.2 Echocardiography 
In vivo TDI echocardiographic analyses was used as a measure of left ventricular cardiac 
dysfunction. The procedure was carried out under anesthesia (1.0% - 2.5% isoflurane mixed 
with 0.5 L/min 100% O2) and blinded to the genotype, at 7-, 10-, 11-, 13- and 15-weeks. Heart 
rates were maintained at 450 - 550 beats per minute. TDI echocardiograph analysis were 
performed using a Vevo 2100 high-resolution imaging system equipped with a 30 MHz 
transducer to measure left ventricular function. The % EF and fractional shortening were 
assessed as a measurement of systolic dysfunction. 
 
2.1.3 Sample collection 
At weekly intervals after the allotted time period, from 6- to 16-weeks of age, animals were 
fasted for 4 hrs before being euthanized by exsanguination. Blood was collected from the 
abdominal vena cava into SST Serum Separation Tubes. The following tissues were collected 
to investigate the respective objectives: liver (to ascertain the onset of NAFLD), skeletal 
muscle (from the quadriceps of the thigh, to verify insulin resistance), and heart (to confirm 
cardiac dysfunction). 
 
2.1.4 Liver enzymes and lipogram 
After collection, SST tubes containing serum were centrifuged at 4000 x g for 15 min at 4 °C, 
after which serum samples were sent to PathCare Medical Diagnostic Laboratories (Cape 
Town, South Africa) for analysis. Serum levels of the liver enzymes ALT and AST were 
measured as an indication of liver damage, which may result from hepatic steatosis. Similarly, 
lipograms for low density lipoprotein (LDL), total cholesterol, and triglycerides were 
determined as an indication of dyslipidaemia. 
 
 Histology 
Histological analysis was performed on the liver in order to determine the onset and severity 
of hepatic lipid accumulation (steatosis). To ensure that the same area of the liver was 
sectioned, frozen liver tissues were sectioned sagittal to the lobe at 10 µm using a Leica 
Cryostat (Leica, Wetzlar, Germany) and transferred onto Superfrost® Microscope Slides 
(Thermo Fisher Scientific, Massachusetts, United States) and kept at -20 °C until staining. 
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2.2.1 Haematoxylin and Eosin stain 
A haematoxylin and eosin (H&E) stain was performed to visualise general tissue morphology. 
Glass slides with liver sections were placed in a metal stain rack and equilibrated to room 
temperature, before being immersed 5 times in dH2O. Slides were then submerged in filtered 
Mayer’s Haematoxylin (Kimix Chemicals, Cape Town, South Africa) for 12 min, followed by a 
10 min wash step in running tap water until the water ran clear, to facilitate staining of the 
nuclei. Thereafter, to stain cytoplasm and acidophilic structures, cells were counterstained 
with Eosin (Kimix Chemicals, Cape Town, South Africa) for 2 min before a final wash step in 
dH2O until the water was clear. Sections were dehydrated by ascending slides 20 x in 95% 
alcohol, and then 100% alcohol before placing slides in a Columbia staining dish containing 
xylene for 1 min. Slides were removed from xylene and coverslips were mounted immediately 
using DPX mounting media (Sigma-Aldrich, Missouri, United States). Using the Nikon Eclipse 
Ti-S ProScan III microscope (Nikon, Tokyo, Japan), the portal areas of each section were 
identified by the proximity of a blood vessel. The central areas of the liver were also identified 
by the absence of portal blood vessels and images were captured of these areas at 400x 
magnification. Images where neither the portal vessel, nor the edge of the tissue was in the 
field were used for histological analysis.  
 
2.2.2 Oil Red-O stain 
To confirm the presence of lipid droplets in the liver, an Oil Red O (ORO) lipid stain was 
performed on the glass slides with liver sections. Briefly, sections were allowed to equilibrate 
to room temperature for 10 min before being immersed for 20 min in Oil Red-O working 
solution (prepared as in Appendix B4). Thereafter slides were removed and rinsed in running 
tap water for 5 min before being counterstained with 0.25% crystal violet solution for 1 min. 
Thereafter, slides were rinsed in running tap water for 5 min and allowed to air dry before 
mounting with buffered glycerol-jelly aqueous mounting media. Images were captured within 
3 days using the Nikon Eclipse Ti-S inverted light microscope (Tokyo, Japan) at 400 x 
magnification. 
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 Gene expression analysis  
2.3.1 RNA extraction 
2.3.1.1 Heart tissue 
Ribonucleic acid (RNA) was extracted using Qiazol® reagent (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. Briefly, 50 mg of left ventricular tissue was cut 
and placed in a 2 mL Eppendorf tube (Eppendorf, Hamburg, Germany) containing a stainless-
steel bead (Qiagen, Hilden, Germany) and 500 µL Qiazol reagent. Tissues were then 
homogenized using a Qiagen TissueLyser (Qiagen, Hilden, Germany) at 25 Hz for 1 min 
followed by incubation on ice for 1 min, a process repeated 4 times. The Eppendorf tubes 
containing the lysed tissues were then centrifuged at 15 000 x g for 10 min at 4 °C and the 
supernatant was transferred to a new 1.5 mL tube. Subsequently, 100 µL of chloroform 
(Sigma-Aldrich, Missouri, United States) was added to each tube, mixed intermittently for 3 
min and centrifuged at 15 000 x g for 15 min at 4 °C. Thereafter, the upper aqueous phase 
was transferred to a new 1.5 mL Eppendorf tube (Eppendorf, Hamburg, Germany) without 
disturbing the white interphase. Precipitation of RNA was achieved by the addition of 250 µL 
isopropanol (Sigma-Aldrich, Missouri, United States) to the samples, which were mixed by 
inversion several times before overnight incubation at -20 °C. The following day, the RNA was 
pelleted by centrifugation at 15 000 x g for 30 min at 4 °C. The supernatant was discarded, 
and the pellet washed with 500 µL of 70% EtOH and centrifuged at 15 000 x g for 15 min at 4 
°C. The wash step was repeated twice, and thereafter the supernatant was discarded and the 
pellet allowed to air dry for 30 min in a PCR hood. Thereafter, the RNA pellet was re-
suspended in 50 μL nuclease-free water (Ambion, Texas, United States) and incubated at 55 
°C for 10 min before the concentration was quantified using a NanoDrop® One 
Spectrophotometer (Thermo Fisher Scientific, Massachusetts, United States) as described in 
section 2.3.2, after which the RNA was stored at -80 °C until further use. 
2.3.1.2 Liver tissue 
Ribonucleic acid was extracted from liver using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Briefly, 30 mg of tissue was cut from 
the right anterior of the liver and placed in a 2 mL Eppendorf tube (Eppendorf, Hamburg, 
Germany) containing a stainless-steel bead (Qiagen, Hilden, Germany) and 600 µL RLT 
buffer. Tissues were then homogenized using a Qiagen TissueLyser (Qiagen, Hilden, 
Germany) at 25 Hz for 1 min followed by incubation on ice for 1 min, a process repeated 4 
times. The Eppendorf tubes containing the lysed tissues were then centrifuged at 15 000 x g 
for 3 min at 4 °C, after which the supernatant was transferred to a new tube and the pellet was 
discarded. One volume of 70% EtOH was added to each tube and mixed by pipetting. The 
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samples were then transferred to an RNeasy spin column, and centrifuged at 15 000 x g for 
15 sec, after which the flow-through was discarded. Subsequently, 700 µL RW1 buffer was 
added to the RNeasy spin column, before the spin column was centrifuged at 15 000 x g for 
15 sec and the flow-through was discarded. Next, 500 µL RPE buffer was added to the spin 
column, centrifuged at 15 000 x g for 15 sec and the flow-through was discarded. This step 
was repeated twice, after which the spin column was placed in a new 2 mL collection tube and 
centrifuged at 15 000 x g for 1 min to completely dry the membrane. The RNeasy spin column 
was placed in a new 1.5 mL Eppendorf tube (Eppendorf, Hamburg, Germany) and 50 µL 
nuclease-free water was added directly to the spin column membrane. The column was 
allowed to stand for 1 min before being centrifuged at 15 000 x g for 1 min to elute the RNA, 
which was subsequently quantified. 
 
2.3.2 RNA quantification  
Ribonucleic acid was quantified using a NanoDrop® One Spectrophotometer (Thermo Fisher 
Scientific, Massachusetts, United States). The NanoDrop® was initialized and blanked by 
pipetting 1 µL of nuclease free water onto the pedestal. Thereafter, 1 µL of each sample was 
added to the pedestal and absorbance was read in triplicate. The average of the three 
readings were used to determine the concentration, while the ratio of 260 nm to 280 nm was 
used to evaluate the purity of the RNA, and the 260 to 230 ratio was used to check for DNA 
contamination. Ratios between 1.8 and 2 were considered acceptable. After quantification, 
RNA was stored at -80 °C until further use. 
 
2.3.3 DNAse treatment of RNA 
To remove DNA contaminants, RNA samples were treated using the Turbo DNA-freeTM kit 
(Ambion, Texas, United States) following the manufacturer’s instructions. Briefly, 1 µL of 
DNAse and 5 µL of DNAse buffer were added to 20 µg of RNA and the reaction volume was 
made up to 50 µL with nuclease-free water (Ambion, Texas, United States). Samples were 
mixed and incubated for 30 min at 37 °C, after which an additional 1 µL DNAse was added, 
followed by a further 30 min incubation at 37 °C. DNAse activity was halted by the addition of 
10 µL DNase inactivation reagent, followed by a 5 min incubation at room temperature, with 
mixing. The samples were then centrifuged at 10 000 x g for 1.5 min and the supernatant was 
transferred to a new 0.5 mL Eppendorf tube (Eppendorf, Hamburg, Germany). RNA 
concentrations were determined using a NanoDrop® One Spectrophotometer (Thermo Fisher 
Scientific, Massachusetts, United States) (Section 2.3.2). 
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2.3.4 Determination of RNA integrity 
Ribonucleic acid integrity was determined using the Agilent 2100 Bioanalyzer and Agilent 
6000 Nano kit (Agilent Technologies, California, United States) according to the 
manufacturer’s instructions. Briefly, bioanalyzer electrodes were decontaminated before use 
by placing them in 350 µL RNaseZAPTM (Invitrogen by Thermo Fisher Scientific, 
Massachusetts, United States) for 1 min, followed by nuclease-free water for 10 sec. Once 
decontaminated, the lid of the bioanalyzer was left open for 10 sec to allow the electrodes to 
dry. To prepare the gel-dye mix, reagents were equilibrated to room temperature for 30 min, 
after which new filtered gel aliquots were prepared: 550 µL RNA gel matrix was filtered in the 
centrifuge at 1 500 x g for 10 min at room temperature and 65 µL aliquots were made. RNA 
6000 Nano dye concentrate was vortexed and spun down, and 1 µL added to a 65 µL aliquot 
of gel matrix. The solution was vortexed and centrifuged at 13 000 x g for 10 min at room 
temperature. 
 
 
Figure 2: Representative image of the Agilent 6000 Nano Chip.  
 
The RNA 6000 Nano chip (Figure 2) was prepared by placing it on the chip priming station 
and adding 9 µL of gel-dye mix into well marked with a circled G. The plunger was adjusted 
to 1 mL, after which the chip priming station was closed, and the plunger pressed down until 
it was held by the clip. After 30 sec the clip was released, and the plunger was allowed to 
decompress for a further 30 sec before opening the priming station. Ribonucleic acid samples 
and RNA ladder were placed in a heating block for 2 min at 70 °C for denaturation. Thereafter, 
9 µL of gel-dye mix was added to each of the two wells marked G, and 5 µL of RNA 6000 
Nano marker was added to each of the sample and ladder wells. Subsequently, 1 µL of sample 
or ladder was loaded into the respective wells. The chip was vortexed at 542 x g for 30 sec, 
placed in the electrode chamber of the bioanalyzer and run within 5 min. The integrity of the 
Stellenbosch University  https://scholar.sun.ac.za
  
29 
 
RNA samples was determined using 2100 Expert Software (Agilent Technologies, Santa 
Clara, California, USA) with a RIN value of ≥ 6.00 being considered acceptable 
 
2.3.5 Synthesis of complimentary DNA  
The synthesis of complimentary DNA (cDNA) from RNA was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, California, United States) 
according to the manufacturer’s instructions. Briefly, 1 µg of RNA was aliquoted into a 0.2 mL 
PCR tube (Axygen, California, USA) and made up to 10 µl with nuclease free water. All 
samples were prepared in duplicate for RT-Plus and RT-Minus reactions. Two master mix 
solutions were prepared containing high quality deoxynucleotide triphosphates (dNTPs), 
reaction buffer, random primers, RNase inhibitor and nuclease-free water. One master mix 
was labelled RT-Minus and served as a negative control, while the other was labelled RT-Plus 
and contained reverse transcriptase. The cDNA synthesis reaction was then prepared by 
adding 10 µL of either RT-Plus or RT-Minus master mix to the respective duplicates of each 
sample (Table 2.1). The tubes were vortexed and spun down before being placed in an 
Applied Biosystems 2720 Thermal Cycler (Applied Biosystems, California, United States). The 
Thermal Cycler conditions were set for 10 min at 25 °C, 120 min at 37 °C, and 5 sec at 85 °C, 
after which the temperature was rapidly lowered to 4 °C. Samples were stored at 4 °C until 
further use. 
 
Table 2.1: Reaction mixture used for cDNA synthesis 
Reagent 
RT-Plus 
Volume/Reaction (µL) 
RT-Minus 
Volume/Reaction (µL) 
Final concentration 
1 µg RNA 10 10 10% w/v 
10x RT buffer 2 2 1X 
25x dNTP mix 0.8 0.8 1X 
10x Random primers 2 2 1X 
RNase inhibitor 1 1 - 
Nuclease-free water 3.2 4.2 - 
Reverse transcriptase 1 - - 
Total volume 20 20  
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2.3.6 Test for genomic DNA 
To test for genomic DNA (gDNA) contamination, cDNA was amplified using β-Actin (ActB) 
exon spanning primers. A reaction mix was prepared containing ActB forward and reverse 
primers, PowerUpTM SYBR® Green Master Mix (Applied Biosystems, California, United States) 
and nuclease-free water to a final volume of 25 μL (Table 2.2).  
 
Table 2.2: Master mix used for the detection of genomic DNA contamination. 
Reagent Volume/Reaction (µL) Final concentration 
PowerUpTM SYBR® Green Master Mix 12.5 1X 
ACTB Forward primer (10 µM) 
5’-GGGCCCGGACTCATCGTACT-3’ 
1 400nM 
ACTB Reverse primer (10 µM) 
5’-GCCTCACTGTCCACCTTCCA-3’ 
1 400nM 
Nuclease free water 9.5 - 
cDNA 1 - 
Total volume 25  
 
A MicroAmpTM Optical 96-well Reaction Plate (Applied Biosystems, California, United States) 
was prepared by adding 1 μL of either RT-Plus or RT-Minus cDNA to each well, after which 
24 µL of SYBR green reaction mix was added. The plate was sealed with MicroAmpTM Optical 
Adhesive Film (Thermo Fisher Scientific, Massachusetts, United States), placed on a plate 
shaker at 500 rpm for 10 min and briefly centrifuged at 3000 x g for 1 min before the plate was 
placed in the Applied Biosystems 7500 Sequence Detection System (Applied Biosystems, 
California, United States) for quantitative PCR analysis. The cDNA was amplified using the 
cycling conditions described in Table 2.3.  
 
Table 2.3: Cycling conditions used to test cDNA for genomic DNA contamination. 
Step Temperature (°C) Time Cycles 
Activation and denaturation 
50 2 min 
1 
95 10 min 
Fluorescence data collection 
95 15 sec 
40 
60 1 min 
Dissociation curve 
95 15 sec 
1 60 1 min 
95 15 sec 
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The quantity of cDNA for each reaction was determined from the default threshold cycle (Ct) 
and baseline obtained during the exponential phase. To determine if gDNA contamination 
could influence quantification, Ct values of the RT-Plus samples were subtracted from the Ct 
values of the corresponding RT-Minus samples. If the difference in Ct values were equal to or 
greater than 10 between the corresponding RT-Minus and RT-Plus strand, the presence of 
contamination was considered to be negligible. 
 
2.3.7 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) analysis  
Quantitative Real-Time gene expression analysis was performed using TaqMan® gene 
expression probe assays (Johnson, et al., 2016) (Table 2.4) (Thermo Fisher Scientific, 
Massachusetts, United States).  
 
Table 2.4: TaqMan® probe assays used in qRT-PCR analysis 
Function Symbol Gene Probe assay 
Housekeeping 
 ACTB Beta actin Mm02619580_g1 
 B2M Beta 2 microglobulin Mm00437762_M1 
 HPRT1 Hypoxanthine phosphoribosyl transferase 1 Mm03024075_m1 
Liver 
Cholesterol 
synthesis 
APOB Apolipoprotein B Mm01545150_m1 
HMGCR 3-Hydroxy-3-Methylglutaryl-CoA Reductase Mm01282499_m1 
Lipid 
synthesis 
SREBF1 Sterol regulatory element binding factor 1 Mm00550338_m1 
FASN Fatty Acid Synthase Mm00662319_m1 
SCD1 Stearoyl-coenzyme A desaturase 1 Mm00448918_m1 
Lipid 
metabolism 
PPARα   
CPT1A Carnitine palmitoyl transferase 1-a Mm01231183_m1 
Heart 
Oxidative 
stress 
NOX4 NADPH oxidase 4 Mm00479246_m1 
Inflammation NFκB Nuclear factor κ B Mm00495541_m1 
Apoptosis CASP3 Caspase 3 Mm01195085_m1 
Fibrosis 
CTGF Connective tissue growth factor Mm01192933_m1 
NPPA Natriuretic peptide precursor A Mm01255747_g1 
Energy 
homeostasis 
PRKAA2 Protein kinase, AMP-activated, alpha 2 
catalytic subunit 
Mm01264789_m1 
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A standard curve was prepared from a 10-fold serial dilution of pooled cDNA(100, 10, 1, 
0.1,0.01, 0.001, 0.0001). cDNA from unknown samples to be tested, was prepared by diluting 
1:5 in nuclease free water. A PCR master mix was prepared by combining 5 µL of 2 x TaqMan® 
Universal PCR Master Mix (Thermo Fisher Scientific, Massachusetts, United States), 3.5 µL 
nuclease-free water, and 0.5 µL TaqMan® gene expression assay per reaction (Table 2.5). 
Plates were prepared by adding 1 µL of sample to a MicroAmpTM Optical 96-well Reaction 
Plate (Applied Biosystems, California, United States) in duplicate, after which 9 µL PCR 
master mix was added to each well. The plate was sealed, placed on a plate shaker and mixed 
at 500 rpm for 10 min and thereafter centrifuged at 3000 x g for 1 min. The plate was then 
placed in an ABI 7500 Sequence Detection System Instrument (Applied Biosystems, 
California, United States) to conduct the qRT-PCR reactions using the PCR cycling conditions 
as described in Table 2.3. The quantity, mean, and standard deviation values were calculated 
by the ABI Standard Quantification software and data was subsequently used to calculate the 
relative expression values. β-Actin (ACT-B) and Hypoxanthine phosphoribosyl transferase 1 
(HPRT1) were used as endogenous housekeeping genes. Gene quantities were normalised 
by dividing the mean quantity of target genes by the mean quantity of the housekeeping genes 
ACT-B and HPRT1 and obtaining a mean of the two values. 
 
Table 2.5: Reaction mixture used to conduct qRT-PCR 
Reagent Volume/Reaction (µL) 
Taqman universal PCR master mix 5 
Nuclease-free water 3.5 
Probe assay 0.5 
cDNA 1 
Total Volume 10 
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 Protein expression by Western blot 
2.4.1 Protein extraction 
To further investigate peripheral insulin resistance, protein was extracted from skeletal muscle 
samples and expression of proteins involved in the insulin signalling pathway was determined. 
Approximately 100 mg of tissue was placed in a 2 mL Eppendorf tube (Eppendorf, Hamburg, 
Germany) and rinsed in cold phosphate buffered saline (PBS) (Lonza, Verviers, Belgium), 
after which the rinse was discarded and 500 µL cold Lysis Buffer and a stainless-steel bead 
was added to the tube. Tissues were then homogenized using a Qiagen TissueLyser (Qiagen, 
Hilden, Germany) at 25 Hz for 1 min followed by incubation on ice for 1 min, a process 
repeated for 4 times. The tubes containing the lysed tissues were then centrifuged at 15 000 
x g for 10 min at 4 °C, after which the supernatant was transferred to a new 1.5 mL Eppendorf 
tube (Eppendorf, Hamburg, Germany) and stored at -80 °C until further use. 
 
2.4.2 Protein concentration determination 
Protein concentrations were determined using the reducing agent compatible and detergent 
compatible (RC DC) protein assay kit (Bio-Rad, California, United States) according to 
manufacturer’s instructions. Sample dilutions (1:20) were prepared by adding 5 µL lysate to 
95 µL nanopore water.  To prepare reagent A’ solution, 20 µL DC reagent S was added to 1 
mL DC reagent A. Subsequently, 5 μL of bovine serum albumin (BSA) standards (Bio-Rad, 
California, United States) [0.125, 0.25, 0.5, 1, 1.5, and 2 mg/ml] and diluted samples was 
added to a clear 96-well plate. Thereafter, 25 μL of reagent A’ and 200 μL of reagent B were 
added to each well containing standards and samples. The plate was mixed on a plate shaker 
at 500 rpm for 10 sec and incubated for an additional 10 min at room temperature before 
measuring absorbance at 630 nm using a SpectraMax i3 plate reader (Molecular Devices, 
California, United States) and Gen 6 software (Molecular Devices, California, United States). 
A standard curve with linear equation (y = mx + c) was generated using absorbance values of 
BSA standards to calculate the concentration of each sample based on its mean absorbance 
value. The concentration of the sample was then determined by multiplying the obtained 
concentration by the dilution factor. 
 
2.4.3 Protein gel electrophoresis 
Sample buffer was prepared by adding 50 µL β-mercaptoethanol (Fluka, Bucharest, Romania) 
to 950 µL 2 x Laemmli Sample Buffer (Bio-Rad, California, United States). Between 30-50 µg 
protein lysates were mixed with sample buffer in a 1:1 ratio and denatured by heating for 5 
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min at 95 °C, and snap-cooled by placing on ice immediately. CriterionTM TGXTM 12% Precast 
Midi Gels (Bio-Rad, California, United States) were placed in a gel electrophoresis tank which 
was then filled with 1x Tris/Glycine/SDS running buffer (Bio-Rad, California, United States). 
Subsequently, 5 µL Precision Plus ProteinTM Western CTM marker (Bio-Rad, California, United 
States), and 30-50 µg protein sample was loaded onto the gel and electrophoresis was 
initiated using the PowerPac HC (Bio-Rad, California, United States) at 150 V for 70 min.  
 
2.4.4 Western blot analysis 
2.4.4.1 Transfer to Nitrocellulose membrane 
Following gel electrophoresis, separated proteins were transferred to a nitrocellulose (NC) 
membrane using Trans-Blot® TurboTM Midi NC transfer packs (Bio-Rad, California, United 
States). The transfer sandwich was assembled in the transfer cassette of a Trans-Blot® 
TurboTM (Bio-Rad, California, United States) and run for 10 min at 25 V and 2.5 A. 
 
2.4.4.2 Ponceau S stain 
Once the transfer was complete, the membrane was removed and marked with a pencil before 
submerging in Ponceau S stain (Sigma-Aldrich, Missouri, United States) and placing on an 
orbital shaker for 10 min. Thereafter the membrane was rinsed gently in dH2O until the 
background was clear and complete protein transfer could be confirmed by the presence of 
red stained bands on the membrane. The stain was then reversed by washing the membrane 
in 1 x Tris-buffered saline with 0.1% Tween 20 (TBS-T) for 5 min (prepared as in Appendix 
B2).  
 
2.4.4.3 Membrane labelling 
The NC membrane containing separated proteins was blocked in 5% (w/v) Skim Milk Powder 
(Sigma-Aldrich, Missouri, United States) in TBS-T for 120 min at room temperature on an 
orbital shaker. Subsequently the membrane was rinsed thrice for 5 min in TBS-T, before being 
incubated in primary antibody in TBS-T overnight at 4 °C on an orbital shaker.  The respective 
antibodies as well as the dilutions used are indicated in table 2.6. The following day, the 
membrane was rinsed thrice for 5 min in TBS-T, before incubating in StrepTactin® HRP 
Conjugate (Bio-Rad, California, United States) as well as horseradish peroxidase (HRP) 
conjugated secondary antibody specific to the host species of the primary antibody, in 2.5% 
(w/v) Skim Milk Powder (Sigma-Aldrich, Missouri, United States) in TBS-T for 90 min. 
Subsequently, the membrane was rinsed thrice for 5 min in TBS-T, before proceeding to 
chemiluminescent detection. Clarity Western Enhanced Chemiluminescence (ECL) substrate 
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(Bio-Rad, California, United States) was prepared by mixing part A and part B in a 1:1 ratio 
before and immersing the membrane therein. The membrane was incubated for 5 min, 
avoiding direct light exposure, before imaging on the Bio-Rad ChemiDoc MP System (Bio-
Rad, California, United States). Protein bands were quantified using Image LabTM Software 
(Bio-Rad, California, United States) and all proteins were normalized to a housekeeping gene, 
β-Actin, which served as the loading control (Johnson, et al., 2016). 
 
Table 2.6: Antibodies and dilutions used for Western blot analysis 
Antibody Dilution Catalogue number Company 
pPI3K 1:500 4228 Cell Signalling 
Pi3K 1:500 5569 Cell Signalling 
pAKT 1:500 9271 Cell Signalling 
AKT 1:500 9272 Cell Signalling 
pAMPK 1:500 2535 Cell Signalling 
AMPK 1:500 2532 Cell Signalling 
GLUT4 1:500 2213 Cell Signalling 
CPT1A 1:1000 Ab53532 Abcam 
Β-actin 1:1000 47778 Santa Cruz 
 
2.4.4.4 Stripping of membranes 
Membranes were stripped by incubating the nitrocellulose membrane for 5 min, in Restore 
PLUSTM Western Blot Stripping Buffer (Thermo Fisher Scientific, Massachusetts, United 
States). Buffer was discarded, and nitrocellulose membrane was washed in TBST thrice for 
10 min on an orbital shaker. Membranes were rinsed in TBS-T before continuing with blocking 
and probing as described in section 2.4.4.3. 
 
 Statistical analysis 
Data are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was 
performed using GraphPad Prism (Version 7.00, California, USA). Groups of data were 
compared with a two-way analysis of variance (ANOVA) followed by Dunnet’s Multiple 
Comparison tests. The unpaired, two-tailed student t-test was used when only two groups 
were compared. Values of p<0.05 were regarded as statistically significant.  
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Chapter 3: Results 
 
 Morphometric Data 
Six- to fifteen-week-old Leprdb/db mice and their lean Leprdb/+ controls were fed a standard 
mouse chow diet for 10 weeks. Body weights and fasting blood glucoses were recorded 
weekly. By 6 weeks of age, the body weights of db/db mice were significantly higher compared 
to their age-matched lean controls (31.75 g ± 0.71 vs. 20.50 g ± 0.55, p < 0.001) and this 
remained significantly higher throughout (Fig 3.1 A). At 8 weeks of age, four-hour fasting blood 
glucose levels of db/db mice were elevated by 65% compared to db/+ controls (13.27 mmol/L 
± 3.60 vs. 8.04 mmol/L ± 2.14, p < 0.05). At 9 weeks of age, fasting blood glucose levels in 
db/db mice increased further and remained above 20 mmol/L for the remainder of the 
experimental time points whereas blood glucose for the db/+ control remained consistently 
low (Fig 3.1 B). Calculated HOMA-IR was slightly elevated in db/db mice when compared to 
db/+ controls (0.48 ± 0.06 vs. 0.20 ± 0.03) at 7 weeks and was significantly increased in db/db 
mice at 15 weeks (1.46 ± 0.50 vs 0.1 ± 0.02, p < 0.001) (Fig 3.1 C). 
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Figure 3.1: Body weights, fasting blood glucose levels and HOMA-IR. Body weights (A), four-hour 
fasting blood glucose levels (B) and HOMA-IR index (C) of leptin receptor deficient mice (Leprdb/db) and 
heterozygous lean controls (Leprdb/+) from 6 to 15 weeks of age were significantly increased compared 
to the db/+ control. Results are presented as mean ± SEM of 8 animals per group. Data were analysed 
using two-way analysis of variance (ANOVA) followed by Dunnet’s Multiple Comparison tests. * p ≤ 
0.05, ***p ≤ 0.001 db/db versus age-matched db/+ control.  
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 Echocardiography 
In the obese state, structural and functional modifications to the myocardium results in cardiac 
hypertrophy and contractile dysfunction, affecting ejection capacity. To investigate this 
pathology, TDI echocardiography was used to determine % EF in db/db compared to db/+ 
controls. At 13 weeks of age db/db mice displayed a significantly reduced % EF when 
compared to db/+ controls (51.40 ± 2.50 vs. 61 ± 4.53, p < 0.05) (Figure 3.2). 
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Figure 3.2: Echocardiography. Percentage ejection fraction of leptin receptor deficient mice (Leprdb/db) 
and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age as determined by tissue doppler 
echocardiography. Results are presented as mean ± SEM of 6 animals per group Data were analysed 
using two-way analysis of variance (ANOVA) followed by Dunnet’s Multiple Comparison tests. * p ≤ 
0.05 versus age-matched control. 
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 Lipogram 
As an indication of dyslipidaemia and a measure of metabolic risk, lipid profiles were 
performed in db/db mice and their heterozygous db/+ controls. At 7 weeks, triglyceride levels 
were significantly elevated in db/db mice when compared to the lean db/+ controls (2.43 
mmol/L ± 0.11 vs. to 0.84 mmol/L ± 0.08, p < 0.001), and levels remained elevated throughout 
the experimental timeframe (Fig 3.3 A). Similarly, serum LDL levels were significantly elevated 
at 7 weeks in the db/db group when compared to the db/+ controls (0.55 mmol/L ± 0.03 vs. 
0.30 mmol/L ± 0.004, p < 0.01) and remained elevated at 13 and 15 weeks, though not 
significant at 10 weeks (0.38 mmol/L ± 0.05 vs. 0.30 mmol/L ± 0.01) (Fig 3.3 B). Furthermore, 
at 7 weeks total cholesterol levels of db/db mice were significantly raised when compared to 
db/+ controls (3.90 mmol/L ± 0.14 vs. 1.90 mmol/L ± 0.04, p < 0.001) and remained elevated 
throughout the study (Fig 3.3 C). 
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Figure 3.3: Serum lipid levels. Triglycerides (A), low-density lipoprotein (LDL) (B), and total 
cholesterol (C) as determined by serum lipogram was increased leptin receptor deficient mice (Leprdb/db) 
when compared to heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age. Results are 
presented as mean ± SEM of 8 animals per group Data were analysed using two-way analysis of 
variance (ANOVA) followed by Dunnet’s Multiple Comparison tests. ** p ≤ 0.01, ***p ≤ 0.001 versus 
age-matched control. 
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 Liver Enzymes 
Aspartate Transaminase and ALT are known markers of liver toxicity. There was a significant 
increase in AST at 13 weeks in the db/db group when compared to db/+ controls (128.75 IU/L 
± 29.48 vs. 50.75 IU/L ± 0.85, p < 0.01) (Fig 3.4 A). Similarly, at 7 weeks, ALT levels were 
significantly higher in the db/db group when compared to db/+ controls (110.33 IU/L ± 13.32 
vs. 46.50 IU/L ± 11.30, p < 0.05) (Fig 3.4 B). While AST and ALT can be used as a measure 
of liver damage, the ratio of AST/ALT can give an indication of the type of liver damage, with 
a high ratio, around 2, associated with alcoholic liver disease, and a ratio lower than 1 
associated with non-alcoholic hepatic lipid accumulation (Sorbi, et al., 1999). The ratio of 
AST/ALT in db/db mice was less than 1 at 7 weeks (0.76 ± 0.07) and remained below 1 
throughout (Fig 3.4 C), indicating the presence of hepatic steatosis. 
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Figure 3.4: Aspartate Transaminase and Alanine Transaminase levels in serum. Levels of 
Aspartate Transaminase (AST) (A), Alanine Transaminase (ALT) (B), and AST/ALT ratio (C) in serum 
of leptin receptor deficient mice (Leprdb/db) remained altered when compared to heterozygous lean 
controls (Leprdb/+) from 7 to 15 weeks of age. Results are presented as mean ± SEM, * p ≤ 0.05, ** p ≤ 
0.01. Data were analysed using two-way analysis of variance (ANOVA) followed by Dunnet’s Multiple 
Comparison tests. ***p ≤ 0.001 db/db versus age-matched db/+ control.  
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 Haematoxylin and Eosin stain of liver sections 
While liver enzymes can be used as a marker of liver damage, histological analysis remains 
the gold standard for confirming the onset of NAFLD. Upon H&E-staining and histological 
analysis of paraffin-embedded liver sections, our results indicated that simple steatosis was 
present at 7 weeks of age and that the severity of hepatic lipid accumulation increased with 
age. Microvesicular steatosis was identified at 7 weeks by the accumulation of multiple, small 
lipid droplets in hepatocytes, as indicated by white arrows (Fig 3.5 B). At 10 weeks 
microvesicular steatosis persisted, with an increased number of hepatocytes displaying lipid 
accumulation. By 13 weeks of age, intracellular lipid accumulation in the db/db group (Fig 3.5 
F) led to hypertrophy with the nucleus of some cells displaced to the side of the cell. This 
phenomenon worsened by 15 weeks of age (Fig 3.5 H), where the steatosis appeared to be 
progressing towards macrovesicular steatosis, where the lipid droplets within the cell merge 
into one and the nucleus is eventually disintegrated.  
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Figure 3.5: Haematoxylin and Eosin stain of liver sections. Photomicrographs of paraffin-embedded 
liver sections of heterozygous controls (Leprdb/+) retained normal morphology (A, C, E, G), while leptin 
receptor deficient mice (Leprdb/db) (B, D, F, H) displayed microvesicular steatosis from 7 to 10 weeks, 
which progressed towards macrovesicular steatosis at 15 weeks of age with displacement of the 
nucleus to the side of the cell. Scale bar = 100 µm, white arrow = microvesicular steatosis, grey arrow 
= hypertrophy, black arrow = nuclear displacement 
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 Gene and protein expression analysis 
3.6.1 Liver gene expression 
3.6.1.1 De novo lipogenesis 
To further investigate hepatic lipid accumulation, genes involved in lipid metabolism and de 
novo lipid synthesis were investigated. The mRNA expression of the transcriptional regulator 
SREBF1, involved in fatty acid biosynthesis, was not significantly altered in db/db mice when 
compared to age-matched db/+ controls at any of the time points (Fig 3.6 A). Interestingly, the 
expression of mRNA for FASN, the enzyme that catalyses fatty acid synthesis, was 
significantly increased at 7 weeks in db/db mice when compared to db/+ controls (1.16 ± 0.18 
vs. 0.25 ± 0.05, p < 0.01) and remained elevated throughout (Fig 3.6 B). Similarly, the 
expression of mRNA for SCD1, an enzyme involved in the synthesis of monounsaturated fatty 
acids, was also significantly increased by 7 weeks in db/db mice when compared to db/+ 
controls (1.03 ± 0.08 vs. 0.20 ± 0.05, p < 0.001) and remained elevated throughout (Fig 3.6 
C). Augmented HMGCR, a rate-controlling enzyme in cholesterol biosynthesis, is known to 
cause an increase in LDL clearance, of which ApoB is the main protein constituent. In this 
study mRNA expression of HMGCR, was significantly increased at 7 weeks in the db/db group 
when compared to db/+ controls (1.29 ± 0.09 vs 0.71 ± 0.13, p < 0.001) and remained elevated 
at 13 and 15 weeks. Expression was also increased at 10 weeks, though not significantly (Fig 
3.6 D). Interestingly, there was no significant change in APOB mRNA expression at any of the 
time points (Fig 3.6 E).  
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Figure 3.6: Expression of lipogenic genes in liver. Expression of lipogenic genes in livers of leptin 
receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age. 
Results are normalized to ACTB and HPRT1, and presented as mean ± SEM of 8 animals per group. 
Data were analysed using an unpaired, two-tailed student t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
versus age-matched control. 
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3.6.1.2 Hepatic fatty acid oxidation 
Long-chain fatty acids, a known inducer of CPT1 modulate fatty acid β-oxidation through the 
activation of PPARα. In this study the expression of PPARα was slightly decreased in db/db 
mice at 7 weeks, though not significantly, and increased at 15 weeks (1.53 ± 0.13 vs. 1.12 ± 
0.10 p < 0.01) (Fig 3.7 A). CPT1 was significantly decreased in db/db mice compared to 
controls (0.63 ± 0.03 vs. 0.99 ± 0.09, p < 0.01) at 7 weeks of age, but not at any of the other 
time points (Fig 3.7 B).  
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Figure 3.7: Expression of lipolytic genes in liver. Expression of genes involved in fatty acid β-
oxidation in livers of leptin receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) 
from 7 to 15 weeks of age. Results are normalized to ACTB and HPRT1, and presented as mean ± 
SEM of 8 animals per group. Data were analysed using an unpaired, two-tailed student t-test. * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus age-matched control.  
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3.6.2 Cardiac gene expression 
In the heart, increased oxidative stress, inflammation and fibrosis leads to the activation of 
pro-apoptotic pathways and ultimately contractile dysfunction. Gene expression of NOX4, a 
major source of oxidative stress, was significantly increased in db/db mice compared to db/+ 
controls at 10 and 15 weeks of age (1.23 ± 0.30 vs. 0.77 ± 0.09, p < 0.05) (Fig 3.8 A). 
Expression of NFκB mRNA, a transcription factor involved in inflammation and cell survival, 
was significantly increased in the db/db group when compared to db/+ controls (1.68 ± 0.09 
vs. 0.69 ± 0.04, p < 0.001) at 10 weeks of age and remained elevated throughout (Fig 3.8 B). 
Connective tissue growth factor (CTGF), a protein involved in fibrosis, also showed 
significantly increased mRNA expression in the obese db/db group when compared to db/+ 
controls (2.08 ± 0.39 vs. 0.98 ± 0.27, p < 0.001) at 15 weeks of age (Fig 3.8 C). Caspase 3 
(CASP3), a known determinant of apoptosis was significantly increased in db/db mice when 
compared to db/+ controls (1.42 ± 0.10 vs. 1.06 ± 0.06, p < 0.05) at 10 weeks of age and 
remained elevated throughout the study (Fig 3.8 D). 
Expression of NPPA mRNA, encoding for Atrial Natriuretic Peptide (ANP), a protein involved 
in cardiac metabolic homeostasis as well as the prevention of maladaptive cardiac 
hypertrophy, was not significantly different between the db/db mice and db/+ controls at any 
of the time points (Fig 3.8 E). Similarly, AMPK, an enzyme involved in maintaining cellular 
energy homeostasis, was not significantly different between the db/db mice and db/+ controls 
at any of the time points (Fig 3.8 F). 
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Figure 3.8: mRNA expression in heart tissue. Expression of mRNA in hearts of leptin receptor 
deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age. Results 
are normalized to ACTB and B2M, and presented as mean ± SEM of 8 animals per group. Data were 
analysed using an unpaired, two-tailed student t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus age-
matched control. 
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3.6.3 Protein Expression by Western Blot 
Insulin resistance is characterised not only by altered circulating insulin levels, but also by 
impaired glucose uptake in peripheral tissues (Wilcox, 2005). Insulin signalling can be 
activated either by the insulin-dependent pathway (IRS/PI3K/AKT) or the insulin-independent 
pathway (AMPK) that results in the translocation of GLUT4 to the cell membrane. Thus, to 
investigate glucose uptake into peripheral tissue, the activation of proteins in this pathway was 
quantified. There was a decrease in the p/tPI3K ratio in db/db mice at 10 weeks (0.17 ± 0.03 
vs 0.10 ± 0.01, p < 0.01) (Fig 3.9 A). This was accompanied by a similar decrease in the 
p/tAKT ratio in db/db mice at 10 weeks (0.23 ± 0.06 vs 0.12 ± 0.03, p < 0.05) (Fig 3.9 B). There 
was no change in the p/t AMPK ratio (Fig 3.9 C). Expression of GLUT4 in the cytosolic fraction 
of skeletal muscle was increased at 13 and 15 weeks of age when compared to db/+ controls, 
though this difference was not statistically significant (Fig 3.9 D). Carnitine 
Palmitoyltransferase-1 (CPT1) is a mitochondrial membrane protein involved in the transport 
of fatty acids into the mitochondria for beta oxidation. CPT1 is inhibited by malonyl-CoA and 
it’s downregulation promotes lipid accumulation and subsequent exacerbation of insulin 
resistance. Protein expression of CPT1 decreased with age and was significantly lower in the 
db/db group than in db/+ controls (0.03 ± 0.004 vs. 0.08 ± 0.22, p < 0.05) at 15 weeks of age 
(Fig 3.9 E). 
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Figure 3.9: Protein expression in skeletal muscle. Ratio of phosphorylated to total protein 
expression of PI3K (p/tPI3K) (A), p/t AKT (B), p/tAMPK (C), and CPT1 (D) in skeletal muscle lysates of 
leptin receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks 
of age, normalised to β-actin as a loading control. Results are presented as mean ± SEM of 6 animals 
per group, Data were analysed using an unpaired, two-tailed student t-test. ** p ≤ 0.01 versus age-
matched control. 
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Chapter 4: Discussion 
 
 Obesity 
Obesity constitutes a major health concern, as it is associated with the development of 
dyslipidaemia, NAFLD, insulin resistance, and subsequent cardiac dysfunction (Kopelman, 
2000; Mantovani, et al., 2015; Fruh, 2017). In the obese state, increased lipolysis is a major 
source of augmented FFA that is invariably associated with increased fatty acid accumulation 
in patients with NAFLD as well as insulin resistance (Turner, et al., 2014; Feng, et al., 2017). 
It has been reported that 80 - 90% of obese individuals also have NAFLD (Gaggini, et al., 
2013), ensuing in the putative belief that NAFLD is the hepatic manifestation of metabolic 
syndrome (Ter Horst & Serlie, 2017; Han & Lee, 2017). Furthermore, the prevalence of NAFLD 
in the general population is between 25% and 30%, while amongst T2DM patients it is up to 
70% (Gaggini, et al., 2013), suggesting that an interplay exists between NAFLD and insulin 
resistance. However, whether obesity-induced NAFLD initiates peripheral insulin resistance, 
or whether peripheral insulin resistance precedes the onset of NAFLD remains to be explored 
(Gruben, et al., 2014). 
As health costs related to metabolic syndrome and cardiovascular disease continue to rise, it 
becomes increasingly important to understand the related disease pathology. Understanding 
the mechanism that links NAFLD and insulin resistance to cardiac dysfunction may assist in 
the identification of therapeutic targets to combat the disease pathology. More so, it may allow 
for the identification and screening of prognostic markers, which may in turn allow for early 
interventions to prevent the onset of disease entirely.  
 
In this study, a leptin receptor-deficient db/db mouse model was employed to investigate the 
disease state. The afore mentioned is a well-established and translatable model for the 
development of T2DM and cardiac dysfunction, in which db/db mice become grossly obese, 
hyperglycaemic and hyperlipidaemic as early as 6 weeks of age, while displaying left 
ventricular dysfunction at 12 weeks of age (Kobayashi, et al., 2000; Hall, et al., 2014; Wang, 
et al., 2014; Dludla, et al., 2017). Our study confirms previous findings, showing that db/db 
mice displayed raised body weight at 6 weeks of age, accompanied by the classical trio of 
hypertriglyceridemia, hypercholesterolaemia, and augmented LDL, characteristic of metabolic 
syndrome (Hur, et al., 2015). 
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Another element of metabolic syndrome includes chronically elevated levels of blood glucose 
and insulin. Blood glucose is naturally increased post-prandially and decreases as insulin 
action facilitates glucose clearance. In a fasted state blood glucose levels are maintained 
through a balance between gluconeogenesis in the liver and glucose uptake by other tissues 
(Röder, et al., 2016). However, in the case of insulin resistance, glucose uptake is not 
facilitated, resulting in the build-up of glucose in the blood, persisting even in the fasted state 
(Abdul-Ghani, et al., 2006). Fasting blood glucose levels can thus be used as an indication of 
possible insulin resistance. Similarly, HOMA-IR is a known method to assess β-cell function 
and insulin resistance from fasting blood glucose level and C-peptide concentrations. As 
HOMA-IR calculation uses both the fasting blood glucose and fasting blood insulin, it gives an 
indication of the ability of insulin to stimulate glucose clearance. High levels of fasting blood 
glucose concurrent with high levels of insulin would thus give a high HOMA score and indicate 
reduced insulin sensitivity (Matthews, et al., 1985).  
Studies such as those done by Dong, et al. (2015) and Lim, et al. (2016) show that both fasting 
blood glucose and HOMA-IR are significantly increased in db/db mice as insulin resistance 
develops. This supports findings in the current study, where fasting blood glucose levels were 
slightly elevated in db/db mice by 7 weeks of age, though not significantly. At the same time, 
HOMA-IR was slightly raised but remained below 1, indicating maintained insulin sensitivity. 
Fasting blood glucose levels were significantly elevated by 8 weeks of age and increased 
dramatically by 9 weeks of age, correlating with changes in muscle insulin signalling at 10 
weeks and possibly indicating the onset of insulin resistance.  
 
 The onset of hepatic lipotoxicity 
In addition to studies investigating T2DM, db/db mice are frequently used as a murine model 
in the examination of NAFLD, as these mice display mild to severe steatosis with associated 
increased aminotransferases (Trak-Smayra, et al., 2011; Liu, et al., 2016). The 
aminotransferases AST and ALT are early markers of hepatocellular damage and are used 
as predictive measures to evaluate an individual at risk for developing NAFLD (Bi, et al., 2014). 
Furthermore, hepatic steatosis due to increased alcohol consumption is frequently linked with 
an AST/ALT ratio > 2, while an AST/ALT ratio < 1 has a strong association with NAFLD (Sorbi, 
et al., 1999; Botros & Sikaris, 2013). A study by Trak-Smayra (2011) found that db/db mice 
with histologically confirmed NAFLD had significantly increased AST and ALT levels, while a 
decrease in NAFLD by a herbal medicine was also accompanied by decreases in the levels 
of these enzymes. In our study, we found that db/db mice displayed increased ALT and AST 
from 7 weeks and 13 weeks, respectively. This was accompanied by an AST/ALT ratio of < 1 
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from 7 weeks onwards, which indicated lipid accumulation and correlated with histological and 
lipogram findings.  
 
While AST and ALT are a widely used to screen for NAFLD, some individuals may present 
with normal levels of liver enzymes throughout the disease progression (Mofrad, et al., 2003) 
and therefore histological analysis remains the gold standard for the conclusive diagnosis of 
NAFLD (Kleiner & Makhlouf, 2017). Initially, NAFLD presents histologically as simple steatosis 
in the form of individual, small lipid droplets within the hepatocyte. This can later progress to 
NASH, where lipid accumulation advances into macrovesicular changes and is accompanied 
by apoptosis, inflammation, and fibrosis (Birkenfeld & Shulman, 2014; Liang, et al., 2014; 
Kleiner & Makhlouf, 2017). In a model characterisation by Trak-Smayra (2011), findings 
showed that db/db mice almost invariably displayed microvesicular steatosis at 13 weeks of 
age, while Kondo, et al. (2013) showed that db/db mice have macrovesicular steatosis and 
NASH at 24 weeks of age. Data presented in this study confirm this phenomenon, where 
obese mice presented with evidence of simple steatosis in the form of microvesicular steatosis 
by the age of 7 weeks. Furthermore, the histological severity of NAFLD increased with age, 
where by 10 weeks there was an increase in lipid accumulation, while at 13 weeks hepatocytes 
were hypertrophic with the nucleus displaced to the periphery of the cell. 
 
NAFLD is considered as the hepatic manifestation of MetS and this has been associated with 
activation of a cascade of metabolic pathways that cause the biosynthesis of saturated fatty 
acids. This is due to enhanced expression of de novo lipogenic genes such as FASN and 
SCD1, which are under the transcriptional control of SREBF1 (Li, et al., 2018). The formation 
of monounsaturated fatty acids is catalysed by SCD1, while FASN is a rate-limiting enzyme 
involved in this process. Ge, et al. (2016) reported that an increase in hepatic triglycerides 
occur as a result of an increase in LCFA synthetic enzymes and not due to increased hepatic 
LCFA uptake. Furthermore, it has been reported that inhibition of FASN in db/db mice, reduced 
the development of steatosis when compared to untreated db/db mice (Kong, et al., 2016), 
while inhibition of SCD1 reduced hepatic triglycerides and steatosis (Iida, et al., 2018). 
Additionally, FASN, SCD1 and HMGCR gene and protein expression was increased in the 
livers of db/db mice and accompanied liver steatosis, the severity of which was ameliorated 
by a herbal compound that targeted these enzymes (Lim, et al., 2016; Su, et al., 2016). This 
was confirmed in the present study where we showed that mice displaying increased hepatic 
expression of SCD1, FASN and HMGCR also presented with an augmented steatotic 
phenotype. Interestingly, no changes in SREBF1 were observed. This is contrary to findings 
by Knebel, et al. (2012), which indicated SREBF1 as a central regulator of lipid metabolism in 
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NAFLD. However, while mRNA can give an indication of gene expression, there are other 
post-translational factors that may play a role in protein activity. In the case of SREBF1, protein 
cleavage is regulated in the endoplasmic reticulum (ER) (Yan, et al., 2007). Especially in the 
hyperlipidaemic state, chronically increased FFA can induce ER stress and promote SREBF1 
activity (Angeles & Hudkins, 2016). This post-translational regulation may thus explain why no 
changes in gene expression were observed by us, and why the downstream transcriptional 
targets were still up-regulated despite this observation.  
 
Furthermore, augmented hepatic expression of PPARα and CPT1 has been associated with 
increased β-oxidation in the liver, which resulted in a decrease in triglycerides, 
aminotransferases and liver steatosis (Chen, et al., 2008; Jia, et al., 2016). In the current 
study, we found that CPT1 expression was decreased in db/db mice at 7 weeks, possibly 
contributing to hepatic lipid accumulation. This corresponds with similar findings by Wortham, 
et al. (2014), where a decrease in CPT1 expression in db/db mice was accompanied by 
hepatic steatosis. In the present study, PPARα expression was increased in the db/db mice 
by 15 weeks of age, though there was no increase in CPT1 expression. We propose that the 
observed increase in PPARα expression could indicate that CPT1 expression and subsequent 
β-oxidation might have been up-regulated at a later time point. This may be due to the 
activation of an adaptive mechanism to combat lipid accumulation, as observed in a study by 
Trak-Smayra, et al. (2011). Additionally, in a study performed by Teng, et al. (2018) the 
authors showed that CPT1 expression was increased in db/db mice at 20 weeks of age. 
 
 The onset of muscle insulin resistance  
To further elucidate the causal role, we investigated peripheral insulin resistance in skeletal 
muscle. In the obese state, dyslipidaemia causes chronic low-grade inflammation, 
accompanied by increased release of FFA in the blood and peripheral tissue (Lomonaco, et 
al., 2012). Augmented FFA uptake results in the generation of excess ceramide and DAG, 
which in turn activates PKCθ (Szendroedi, et al., 2014). Increased PKCθ activation promotes 
the phosphorylation of IRSSer307, preventing the phosphorylation of IRSTyr612 in response to 
insulin binding to the insulin receptor (Ragheb, et al., 2009). This reduces the capacity of the 
pPI3KTyr688/pAKTSer473 complex to inhibit glycogen synthesis while increasing GLUT4 
expression and transport to the plasma membrane (Paz, et al., 1999; Brewer, et al., 2014). 
Sharma, et al. (2015), showed that decreased phosphorylation of IRS, PI3K and AKT in 
skeletal muscle of 12-week old db/db mice resulted in the inhibition of GLUT4 
translocation/activity. This is further supported in a study by Zheng, et al. (2015) in which 
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observations included decreased p/t ACC, AKT and GSK3β in skeletal muscle of db/db mice 
at 16 weeks of age. 
  
This correlated with our findings, which showed a decrease in the phosphorylation of PI3K as 
well as AKT at 10 weeks of age, with a concomitant increase in the amount of GLUT4 in the 
cytosolic fraction of skeletal muscle at 10 and 15 weeks, respectively. This increased 
subcellular cytosolic fraction of GLUT4 suggest an impaired translocation of GLUT4 to the 
plasma membrane, due to increased insulin resistance. In support of this, Samad, et al. (2017) 
found that GLUT4 translocation to the plasma membrane was significantly reduced in insulin 
resistant db/db mice when compared to insulin-sensitive controls.  
 
Glucose uptake can also be activated via the insulin-independent AMPK pathway. AMPK is 
activated in response to cellular energy levels (Hardie, et al., 2016) and promotes GLUT4 
translocation independent of the IRS/AKT pathway (Manna & Jain, 2015). This was displayed 
in a study by Duan, (2017), which showed that activation of AMPK by a herbal extract in db/db 
mice led to increased expression of GLUT4 and significant improvement of hyperglycaemia. 
However, data obtained in our study showed no alterations in AMPK activation, indicating that 
glucose uptake did not occur via this pathway. This corresponds with findings by Kang, et al. 
(2017) which also found that there was no significant difference in AMPK phosphorylation 
between db/db mice and lean controls. 
 
Fatty acid oxidation and glucose oxidation are major fuel sources in muscle and heart tissue. 
To meet the energy demand of the cell, depending on the disease state of the organism and 
substrate availability, there will be inter-regulation between fatty acids and glucose as the 
preferred substrate, a phenomenon termed the Randle cycle (Randle, 1998). It has been 
indicated that the preferred substrate choice may contribute to the development of insulin 
resistance (Zhang, et al., 2010). Most studies are in support of the concept that β-oxidation is 
increased in insulin-resistant muscle tissue from obese animals, due to the unavailability of 
glucose and excess availability of FFA. In the present study, due to the decrease in glucose 
uptake in the muscle of db/db mice, it might be expected that there would be a subsequent 
increase in fatty acid β-oxidation to compensate for energy needs. 
However, in our study we observed a decrease in CPT1 protein expression in db/db mice at 
15 weeks, which infers that beta oxidation was decreased. This may be caused by an increase 
in lipogenesis and subsequent inhibition of lipolysis. Lipogenesis is activated when excess 
FFA, overflow from the adipose tissue, are metabolised into triacyl glycerol (TAG) for storage. 
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Malonyl-CoA, an intermediate of TAG synthesis, inhibits CPT1 and subsequently β-oxidation. 
As CPT1 is a mitochondrial protein, differences between the disease states may have been 
more evident if mitochondrial fractions instead of whole-cell lysates were used.  
 
Muscle insulin resistance can be attributed to an increase in FFA flux and fatty acid β-
oxidation, as the intracellular accumulation of lipid intermediates can inhibit insulin signalling 
(Takeuchi, et al., 2018). However, therapies aimed at decreasing β-oxidation may not be 
effective in the prevention of insulin resistance, as defects in mitochondrial substrate oxidation 
are related to lipid build-up, which can cause an inflammatory response and subsequent 
insulin resistance (Goodpaster & Wolf, 2004). The most effective treatment to alleviate lipid- 
induced insulin resistance would thus likely be to simply reduce the availability of FFA by 
dietary intervention. 
 
 The onset of cardiac dysfunction  
Diabetes and NAFLD are known risk factors for the development of cardiac dysfunction. 
Chronic hyperglycaemia and hyperlipidaemia cause glucolipotoxicity, with deleterious 
consequences to the myocardium. Glucolipotoxicity modulates key signal transduction genes 
in processes that regulate bioenergetics, oxidative stress, inflammation, fibrosis, and 
apoptosis, compromising cardiac structure and function.  
 
A key enzyme in the electron transport chain, NOX transfers electrons from NADPH. The 
NOX4 isoform is found specifically in cardiac myocytes and is a potent inducer of oxidative 
stress. Kuroda, et al. (2010) found that NOX4 knock-out mice presented with attenuated 
cardiac hypertrophy, fibrosis and apoptosis, while NOX4 over-expression was a major source 
of mitochondrial oxidative stress. This correlated with our results, which showed an increase 
in NOX4 expression in db/db mice by 10 weeks of age, concurrent with hyperglycaemia and 
hyperlipidaemia  
The above was accompanied by cardiac inflammation, as seen in db/db mice at 10 weeks of 
age by an increase in NFκB expression, one of the major transcription factors associated with 
pro-inflammatory signalling (Zhao, et al., 2015). This is supported by a study done by 
Madonna, et al. (2013), which showed that 12-week-old obese, diabetic db/db mice had 
increased NFκB expression in the heart. Chronic NFκB activation in the heart has been 
associated with inflammation, ER stress response, fibrosis and cell death (Gordon, et al., 
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2011). Conversely, inhibition of NFκB by Resveratrol attenuated cardiac oxidative stress and 
diabetic complications (Bagul, et al., 2015).  
 
Oxidative stress and inflammation affect fibroblast activation and ECM deposition in tissues 
such as the myocardium (Ayoub, et al., 2017). As a potent mediator of ECM deposition and 
subsequent fibrosis, CTGF is found to be increased in the tissues, including the heart, of 
diabetic models. Rawal, et al. (2017) found that CTGF has increased in the hearts of diabetic 
humans as well as db/db mice, and that it was associated with fibrotic remodelling. This 
correlates with findings in the current study, which showed a definite increase in CTGF 
expression in the hearts of 15-week old db/db mice. Chen, et al. (2018) also showed that 
inhibition of CTGF reduces collagen deposition and myocardial fibrosis and improves cardiac 
dysfunction. This may imply that an increase in CTGF expression and subsequent fibrosis 
causes a decrease in the contractility of the myocardium, leading to the decline in cardiac 
function and %EF. 
 
Inflammation, ROS, fibrosis, and dysregulation of leptin lead to cardiomyocyte apoptosis by 
lipotoxic pathways. Trivedi 2008 shows that cleaved casp3, pro-casp3 and apoptotic bodies 
are increased in the hearts of 8 - 12-week old db/db mice and that this phenomenon increased 
with age. In the current study CASP3 expression was significantly increased in db/db mice at 
10 weeks of age, corresponding with inflammation and ROS signaling. It is interesting to note 
that CASP3 expression was increased prior to the increase in CTGF expression, as fibrosis 
is a strong driver of apoptosis. Possible explanations for this is that CASP3 expression was 
increased by factors other than fibrosis, such as ROS/inflammation, or that ROS/inflammation 
initiated activation of TGFβ, which is known to play a role in cardiac dysfunction (Khalil, et al., 
2017). 
 
The alterations in gene expression observed in the present study was accompanied by a 
significant reduction in % EF in db/db mice by 13 weeks of age, confirming a decline in the 
functioning of the heart. This correlates with findings by Faita, (2018) in a model 
characterisation study, which also showed that db/db mice had reduced % EF and cardiac 
function at 13 weeks of age. 
 
ANP (NPPA) helps prevent hypertrophy by controlling cardiac remodelling. In NPPA knock-
out mice, marked cardiac hypertrophy was observed, despite dietary and pharmacological 
treatment (Feng, et al., 2003). Similarly, Wang, et al. (2017) found that there was a significant 
increase in ANP protein expression in db/db mice compared to wild-type mice, and that this 
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was correlated with cardiac hypertrophy. Our findings, however, showed that there was no 
alteration in NPPA gene expression. This may be because proANP is localised mainly in the 
cardiac atrium and released in response to stress. It is thus possible that there was not yet 
atrial stress at this stage of the disease progression. This is supported by Zois, et al. (2017) 
who found no changes in cardiac ANP expression in insulin resistant human males.  
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Chapter 5: Conclusion 
 
In summary, results obtained showed that db/db mice were obese and dyslipidaemic by 7 
weeks of age. At this time, obese mice also presented with simple steatosis in the liver, 
accompanied by increased expression of lipogenic genes and liver enzymes indicative of 
hepatic lipotoxicity. Fasting blood glucose, HOMA-IR and protein expression confirmed that 
insulin resistance was not yet present at the onset of NAFLD. Gene expression and 
echocardiography indicated the onset of cardiac dysfunction between 10 and 13 weeks of 
age, following the development of NAFLD and insulin resistance (Figure 5).  
 
Though several studies have shown that peripheral insulin resistance precedes the onset of 
hepatic steatosis, this study reported that hepatic lipid accumulation and lipotoxicity preceded 
the onset of peripheral insulin resistance that leads to cardiac abnormalities. We further 
speculate that, in the current “genetic” db/db mouse model, NAFLD might be the main driver 
of insulin resistance and subsequent cardiac dysfunction. 
 
 
Figure 5: Summary of findings in the present study. In a leptin receptor-deficient (Leprdb/db) mouse 
model, hepatic steatosis and lipotoxicity was present at 7 weeks of age, preceding the onset of 
peripheral insulin resistance at 10 weeks and cardiac dysfunction at 13 weeks. Illustrations created 
using www.somersault1824.com.  
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In conclusion, the prevalence and financial burden of lifestyle-associated diseases 
emphasizes the importance of finding treatment or preventative therapies for these conditions. 
It is evident that there is much interplay between the components of the metabolic syndrome, 
and these connections provide an important avenue for research in order to better understand 
the disease pathology. Contradictory evidence still exists regarding the order of onset of 
NAFLD and insulin resistance, as well as the role that NAFLD plays in the development of 
insulin resistance. However, the current study provides strong evidence that NAFLD plays a 
casual role in the development of peripheral insulin resistance, and subsequent time 
dependant onset of cardiac dysfunction. 
 
 We hypothesize that there is a difference between the pathophysiology of the “genetic” and 
“metabolic” causes of NAFLD. Where, in a genetically modified model such as the db/db 
mouse model used in this study, insulin resistance appears to be a consequence of NAFLD, 
whereas in a high-fat-high-sugar diet, insulin resistance is more likely to precede and 
contribute to the development of NAFLD.  Furthermore, it is likely that the relationship between 
insulin resistance and NAFLD is a vicious cycle: insulin resistance can cause or exacerbate 
existing hepatic lipid accumulation, which can then aggravate hepatic and peripheral insulin 
resistance. We thus propose that it is important to investigate genetic and metabolic NAFLD 
independently, and that this may allow for a more individualized approach to be taken in the 
development of effective screening tests or therapeutics. 
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Chapter 6: Limitations and Future Outlook 
 
The model used in this study may be considered a limitation, as it is more representative of 
“genetic” NAFLD and may not be translatable to the “metabolic” development of the disease. 
The alterations in leptin signalling may have had an underlying effect of disease progression 
that may not be present in all cases. To address this, future studies should employ and 
compare both a genetic model as well as a HFHS diet-induced model, where the genetic 
(db/db model ) are fed both ar standard chow, or a HFHS diet. 
 
While the mouse model used is time- and cost-effective, the small body size severely limits 
the amount of tissue and serum that can be collected. This caused limitations in the present 
study, as a sufficient amount of serum to quantify insulin levels could only be collected at some 
of the time points. Similarly, collected heart tissue was only large enough to extract RNA, and 
protein expression analysis could not be performed. In future, a larger murine model could be 
employed, such as a HFHS diet fed Wistar rat and Zucker fatty rats. To more clearly identify 
the onset of insulin resistance, future research should include glucose tolerance tests on 
experimental animals, as well as collection of pancreatic and adipose tissue to investigate the 
onset of insulin resistance in different sites in the body. Skeletal muscle protein lysates should 
also be separated into cytosolic and membrane fractions to see GLUT4 translocation, and 
mitochondria could be isolated to more accurately quantify CPT1 and other mitochondrial 
proteins.  
 
While gene expression profiling by mRNA can give some information, it is also important to 
validate findings with protein expression. In future studies, protein activity should be analysed 
using protein assays, to support gene expression findings. Specifically, in the case of 
SREBF1, where no changes in gene expression were observed, but there was still activation 
of its downstream targets. To support findings of hepatic lipid accumulation and NAFLD, and 
to draw a comparison between the db/db and db/+ groups, the hepatic triglyceride content of 
each animal will be quantified in future. 
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Appendix A: List of reagents, consumables and equipment 
Table A1: Reagents and consumables 
Reagent/consumable 
Catalogue 
number 
Company 
0.2 mL PCR Tubes 32102051 Axygen, Union City, California, USA 
0.5 mL Eppendorf safe-lock 
tubes 
0030 123.301  Eppendorf, Hamburg, Germany  
1.5 mL Eppendorf safe-lock 
tubes 
0030 123.328  Eppendorf, Hamburg, Germany  
2 mL Eppendorf safe-lock tubes 0030 123. 344 Eppendorf, Hamburg, Germany  
15 mL centrifuge tubes 602072  
NEST Biotechnology, Jiangsu China 
Wuxi  
50 mL centrifuge tubes 601001  
NEST Biotechnology, Jiangsu China 
Wuxi  
96-well plate CI59018 Sigma-Aldrich, Missouri, United States 
β-mercaptoethanol 63880 Fluka, Bucharest, Romania 
Chloroform 136112-00-0  Sigma-Aldrich, Missouri, United States 
CriterionTM TGXTM 12% Precast 
Midi Gels  
5671043 Bio-Rad, California, United States 
Crystal violet  
Kimix Chemicals, Cape Town, South 
Africa 
DPX mounting media 6522 Sigma-Aldrich, Missouri, United States 
Eosin  
Kimix Chemicals, Cape Town, South 
Africa 
Ethanol 2875  Sigma-Aldrich, Missouri, United States 
OneTouch Select®, Glucose 
Meter 
 LifeScan Inc., California, United States 
Isopropanol  I9516  Sigma-Aldrich, Missouri, United States 
Lysis Buffer   
Laemmli Sample buffer 161-0737 Bio-Rad, California, United States  
Methanol 1070182511  Merck, New Jersey, United States 
MicroAmpTM Optical Adhesive 
Film 
43-119-71 
Thermo Fisher Scientific, 
Massachusetts, United States 
MicroAmpTM Optical PCR 96-
well clear plates 
N8010560  
Applied Biosystems, California, United 
States 
Myer’s Haematoxylin  
Kimix Chemicals, Cape Town, South 
Africa 
NaCl 53014 Sigma-Aldrich, Missouri, United States 
Nuclease-free water Am9937  Ambion, Texas, United States 
Oil Red-O  
Kimix Chemicals, Cape Town, South 
Africa 
OneTouch Select®, Glucose 
Meter 
 LifeScan Inc., California, United States 
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PBS BE17513F Lonza, Verviers, Belgium 
Ponceau S P23295  Sigma-Aldrich, Missouri, United States 
PowerUpTM SYBR® Green 
Master Mix 
A25742 
Thermo Fisher Scientific, 
Massachusetts, United States 
Precision Plus ProteinTM  
Western CTM marker 
1610385 Bio-Rad, California, United States 
Qiazol 79306  Qiagen, Hilden, Germany  
Restore PLUSTM Western Blot 
stripping buffer 
46430 
Thermo Fisher Scientific, 
Massachusetts, United States 
RNaseZAPTM AM9780 
Invitrogen by Thermo Fisher Scientific, 
Massachusetts, United States 
Skim Milk Powder 70166 Sigma-Aldrich, Missouri, United States 
StrepTactin® HRP Conjugate 1610381 Bio-Rad, California, United States 
Superfrost® Microscope Slides 1255014 
Thermo Fisher Scientific, 
Massachusetts, United States 
TaqMan® Probe Assays 4331182 
Thermo Fisher Scientific, 
Massachusetts, United States 
TaqMan® Universal PCR 
Master Mix 
4304437 
Thermo Fisher Scientific, 
Massachusetts, United States 
TGX Tris/Glycine/SDS running 
buffer 
1610772 Bio-Rad, California, United States 
Trans-Blot® TurboTM Midi NC 
transfer packs 
BBRD1704159 Bio-Rad, California, United States 
Tris-base 93352 Sigma-Aldrich, Missouri, United States 
Tween 20 58980C  Sigma-Aldrich, Missouri, United States 
Xylene  
Kimix Chemicals, Cape Town, South 
Africa 
 
A2: Kits 
Kit 
Catalogue 
number 
Company 
Agilent 6000 Nano kit 1511 Agilent Technologies Inc. 
Bio-Rad RC DC protein kit 500-0201  Bio-Rad, California, United States 
BSA standards 5000007 Bio-Rad, California, United States 
ClarityTM Western ECL substrate 1705060  Bio-Rad, California, United States 
High capacity cDNA kit PN 4375575 
Applied Biosystems, California, United 
States 
Insulin ELISA  Merck 
RNeasy® mini kit  74106  Qiagen, Hilden, Germany  
Turbo DNA-FreeTM kit AM1907  Ambion, Texas, United States  
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A4: Equipment 
Equipment 
Product 
Number 
Supplier 
2100 Expert Software  
Agilent Technologies, Santa Clara, 
California, USA 
2720 Thermal Cycler 4413750  
Applied Biosystem, California, United 
States  
ABI 7500 Real Time PCR 
system 
4351104  
Applied Biosystem, Foster City, 
California, United States  
Agilent Bioanalyser 
G2946-
90004  
Agilent Technologies,Santa Clara, 
California  
Benchtop Centrifuge SL16R  
Thermo Fisher Scientific, 
Massachusetts, United States 
ChemiDocTM MP Imaging 
System 
734BR0212 Bio-Rad, California, United States 
GraphPad Prism 7  
GraphPad Software, La Jolla, 
California, USA 
Heating Block S62927099 Labnet 
ImageLab Software  Bio-Rad, California, United States 
Leica Cryostat CM1860 Leica, Wetzlar, Germany 
NanoDrop® One 
Spectrophotometer  
269309102 
Thermo Fisher Scientific, 
Massachusetts, United States 
Nikon Eclipse Ti inverted 
microscope 
Ti inverted  Nikon, Tokyo, Japan  
Orbital Shaker  Torrey Pines Scientific 
pH Meter 702038 Lasec, Cape Town, South Africa 
PowerPacTM HC 165-8025  Bio-Rad, California, United States 
Softmax Pro6 Software  
Molecular Devices, Sunnydale, 
California, United States 
SpectraMax® i3 plate reader  
Molecular Devices, Sunnydale, 
California, United States 
Stainless Steel Beads 69989 Qiagen, Hilden, Germany 
TissueLyser 85300  Qiagen, Hilden, Germany  
Trans-Blot® TurboTM 1704070 Bio-Rad, California, United States 
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Appendix B: Preparation of reagents 
B1: 10 x Tris-buffered saline (TBS) stock solution 
The 10x TBS stock solution was prepared by dissolving 48.44 g Trizma-Base and 160.12 g 
NaCl in 1.8 L dH2O. The pH was adjusted to 7.6 by gradually adding concentrated HCl, and 
the volume was topped up to 2 L with dH2O. Stored at 4 °C. 
 
B2: 1 x TBS-T working solution 
The 1 x TBS-T working solution was prepared by adding 200 mL of 10 x TBS stock solution 
to 1800 mL dH2O and 2 mL Tween 20. Stored at 4 °C. 
 
B3: Transfer buffer 
Transfer buffer was prepared by combining 200 mL 5 x transfer buffer (Bio-Rad, California, 
United States), 200 mL absolute ethanol and 600 mL dH2O. Stored at room temperature. 
 
B4: Oil Red-O (ORO) stain 
Oil Red-O (ORO) stock solution was prepared by dissolving 0.9 g Oil Red O in 180 mL 
isopropanol and Dextrin stock solution was prepared by dissolving 1.2g Dextrin in 120 mL 
distilled water. Oil Red O working solution was prepared fresh before use by adding 30ml Oil 
Red stock to 20 mL Dextrin stock. The working solution was filtered before use.  
 
B5: Crystal Violet 
Crystal Violet working solution was prepared by diluting 25 mL 0.5% Crystal Violet in 25 mL 
distilled water. 
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Abstract: The global obesity epidemic has been associated with various metabolic disorders, including 
insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). Insulin resistance, a hallmark of 
NAFLD, is an established risk factor for type 2 diabetes (T2D) and cardiac dysfunction. While various 
factors that contribute to cardiac dysfunction have been identified, it is not evident whether NAFLD 
is a cause or consequence of muscle IR that drives changes in cardiac structure. Thus, to better 
understand the pathophysiology of NAFLD, this study sought to characterize the order of onset of 
NAFLD and muscle IR in the development of diabetes-induced cardiac dysfunction. Six- to sixteen-
week-old male Leptin receptor deficient (Leprdb/db) mice and their lean littermate controls (Leprdb/+) 
were monitored weekly to measure fasting blood glucose, body weight, and heart function. Serum 
was collected weekly to measure lipogram and liver enzymes. Liver tissues were stained with 
haematoxylin and eosin to determine onset of hepatic steatosis, while gene and protein expression 
analysis were performed on liver, muscle and heart tissue to determine the molecular basis and onset 
of NAFLD, muscle IR and cardiac dysfunction. Data obtained showed that Leprdb/db mice were 
overweight and dyslipidaemic, with increased fasting blood glucose by 7 weeks of age. Histological 
analysis and protein expression of lipogenic genes confirmed the presence of mild hepatic steatosis, 
which increased in severity as the animal aged. Interestingly, muscle insulin resistance was not 
present at the onset of NAFLD. However, from 10 weeks onwards, a decrease in muscle 
phosphorylated PI3K/AKT signalling was observed and this was concomitant to an increased in 
cytosolic GLUT4 protein expression. Gene expression analysis confirmed an increase in oxidative 
stress, inflammation, and apoptosis in the heart of Leprdb/db mice by 10 weeks with a reduction in 
ejection fraction observed by 13 weeks. In summary, our data suggest that, contrary to the general 
believe, hepatic steatosis preceded and likely contributes to the development of IR and subsequent 
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cardiac dysfunction in a Leprdb/db mice model. However, we speculate that the observed effect could 
be dependent on the “metabolic model” under study as well as “genetics” and thus require further 
investigation. 
Keywords: Alanine aminotransferase, Aspartate aminotransferase, Cardiovascular dysfunction, 
Hepatic steatosis, Muscle insulin resistance, Nonalcoholic fatty liver disease (NAFLD), Triglycerides 
1. Introduction
Cardiovascular diseases remain the leading cause of global deaths, with 17.9 million individuals 
dying of heart disease in 2016 [1]. High blood pressure, increased triglycerides, low-density 
lipoproteins (LDL), cholesterol and smoking are key risk factors associated with cardiac dysfunction, 
while conditions such as binge drinking, poor diet, and physical inactivity, are modifiable risk factors 
known to aggravate the epidemic, placing individuals at increased risk for heart failure.  
The pathophysiology associated with cardiovascular dysfunction is mainly linked to diabesity-induced 
glucolipotoxicity. According to the World Health Organization (WHO), it is estimated that 39% of 
adults worldwide are overweight and obese (BMI ≥ 25). In South Africa this number is doubled with 
61% of South Africans being overweight and obese, with obesity strongly linked to de novo lipogenesis 
[2,3]. In the obese state impaired lipid metabolism leads to excessive fat accumulation in hepatocytes, 
which is a prime cause of nonalcoholic fatty liver disease (NAFLD). NAFLD is a feature of metabolic 
syndrome and main driver of insulin resistance (IR), and as such, both conditions are linked to visceral 
adiposity and dyslipidemia. This has been confirmed in, numerous dietary intervention studies, 
reporting on IR and excessive serum fatty acids as pivotal drivers in the development of NAFLD [4-6]. 
More importantly, NAFLD and IR have become common diseases that affect western societies and 
remain key in the development and onset of type 2 diabetes mellitus (T2DM). With the mentioned 
diseases aggravating metabolic syndrome Hence, it is important to delineate the role NAFLD plays in 
the development of IR in order to improve or better current therapeutics. 
To date, conflicting evidence exists regarding the order of onset, making it difficult to develop effective 
therapies. While most studies support the notion that IR causes hepatic steatosis [7-9], very few support 
IR being a consequence of NAFLD [10,11]. It has been well documented that insulin has a dual effect 
on the liver through its control of de novo lipogenesis and gluconeogenesis. During systemic insulin 
resistance, the ability of insulin to blunt free fatty acid (FFA) released from the adipocytes is no longer 
effective. This results in an excessive influx of serum triglycerides into the hepatocytes, causing the 
onset of simple steatosis [12]. This increased lipid overflow stimulates de novo lipogenesis and 
gluconeogenesis, whilst inhibiting pathways associated with beta (β)-oxidation, which further 
exacerbates oxidative stress while promoting inflammation, fibrosis and subsequent microvesicular 
steatosis [10,13,14]. On a molecular basis, excessive de novo lipogenesis is said to activate sterol 
regulatory element binding protein 1c (SREBP-1c), a transcription factor, which in turn increases the 
expression of lipogenic genes such as Fatty acid synthase (FASN), Sterol-CoA Desaturase (SCD) and 3-
Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) to further increase lipid accumulation and 
hepatotoxicity [7].  
Alternatively, in support of NAFLD playing a casual role in IR, a scarcity of data exists. A decade ago, 
Ibdah et al. in 2005, proposed that inhibition of mitochondrial β-oxidation might play a significant role 
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in the development of NAFLD and subsequent IR [15]. The authors elegantly showed that by inhibiting 
mitochondrial β-oxidation, fatty acids might cause the “first hit” in the onset of hepatic steatosis 
subsequently followed by IR [15]. More recent evidence also suggests that an influx of FFA due to 
overexpression of SREBP-1c in mice increases hepatic steatosis and subsequent IR [12]. Similarly, in a 
knock-down of carbohydrate responsive element-binding protein (ChREBP) in an ob/ob mouse model, 
liver-specific inhibition of ChREBP markedly improved hepatic steatosis, plasma triglycerides, and 
non-esterified fatty acid, while restoring insulin signaling in muscle and white adipose tissue [11]. A 
similar phenomenon was observed when mice, on a high-fat-diet, that constitutively express carnitine 
palmitoyl transferase (CPT1a), were found to be protected against the development of hepatic steatosis 
and systemic IR.  
However, none of the mentioned findings was able to elaborate if NAFLD is a cause or consequence of 
IR that drives the cardiovascular pathology. Hence, to better understanding the conundrum that exists 
between NAFLD, IR and cardiovascular disease (CVD) this study will investigate whether NAFLD or 
muscle IR initiates the pathology that leads to the changes in cardiac structure and function, using a 
leptin-receptor-deficient (Lepr) diabetic (db/db) mice model. 
2. Results
2.1. Morphometric analysis 
Six- to fifteen-week-old db/db mice and their lean db/+ controls were fed a standard mouse chow 
diet for 10 weeks. Body weights and fasting blood glucose were recorded weekly. By 6 weeks body 
weights of db/db mice were significantly higher compared to db/+ (31.75 ± 0.71 compared to 20.50 ± 
0.55, p < 0.001) and this remained significantly increased throughout (Fig.1A). Four-hour FBG levels of 
db/db mice were significantly raised by 8 weeks (65%) when compared to db/+ controls (13.27 ± 3.60 
compared to 8.04 ± 2.14, p < 0.05). A further increase in FBG levels at 9 weeks was observed in db/db 
mice, with levels surging above 20 mmol/L (Fig. 1B). The degree of IR was estimated by using the 
Homeostasis Model of Assessment (HOMA-IR), this was only determined for 6 and 15 weeks, due to 
limited availability of serum. At 7 weeks no significance difference was observed between the db/db 
and db/+ group. However, at 15 weeks HOMA-IR was significant different between the two groups. 
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Figure 1: Body weights, fasting blood glucose levels and HOMA-IR. Body weights (A), four-hour 
fasting blood glucose levels (B), and HOMA-IR (C) were significantly different in leptin- receptor-
deficient mice (Leprdb/db) when compared to their age-matched heterozygous lean controls (Leprdb/+). 
Results are presented as mean ± SEM of n=8 animals per group, * p ≤ 0.05, ***p ≤ 0.001 db/db versus 
age-matched db/+ control. 
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2.2. Echocardiography analysis 
In the obese state, increased inflammation and oxidative stress result in structural and functional 
modifications to the myocardium leading to reduced cardiac contractility (EF<60%). As shown in Fig. 
2, after 11 weeks of age, EF was significantly lower in db/db when compared to db/+ controls (Fig. 2). 
Figure 2: Echocardiography. After 11 weeks of age, left ventricle ejection fraction of leptin receptor 
deficient mice (Leprdb/db) was significantly impaired when compared to both normal values (>60%) and 
heterozygous lean controls (Leprdb/+). Results are presented as mean ± SEM of n= 8 animals per group, * 
p ≤ 0.05 versus age-matched control. 
2.3. Serum lipid profile as markers of cardiovascular risk 
As an indication of dyslipidemia and a measure of metabolic risk, lipid profiles were performed 
in db/db mice and their heterozygous db/+ controls. At 7 weeks, triglyceride levels were significantly 
elevated in db/db mice when compared to the lean db/+ controls (2.43 mmol/L ± 0.11 compared to 0.84 
mmol/L ± 0.08, p < 0.001), and levels remained raised throughout the experimental timeframe (Fig 3 A). 
Similarly, serum LDL levels were significantly elevated at 7 weeks in the db/db group when compared 
to the db/+ controls (0.55 mmol/L ± 0.03 compared to 0.30 mmol/L ± 0.004, p < 0.01) and this was evident 
until termination of the experimental conditions, though no significance was observed at 10 weeks (0.38 
mmol/L ± 0.05 compared to 0.30 mmol/L ± 0.005) (Fig. 3B). Furthermore, at 7 weeks total cholesterol 
levels of db/db mice were significantly raised when compared to db/+ controls (3.90 mmol/L ± 0.14 
compared to 1.90 mmol/L ± 0.04, p < 0.001) and remained elevated throughout the study (Fig. 3C). 
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Figure 3. Serum lipid levels. Triglycerides (A), low-density lipoprotein (LDL) (B), and total 
cholesterol (C) were increased in leptin receptor-deficient mice (Leprdb/db) when compared to 
heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age. Results are presented as mean ± SEM of 
n=8 animals per group, ** p ≤ 0.01, ***p ≤ 0.001 versus age-matched control. 
2.4. Liver toxicity 
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2.4.1 Liver enzymes as early markers of liver toxicity 
Both AST and ALT are markers of liver injury. AST were significantly elevated at 13 weeks in 
db/db group when compared to db/+ controls (129 IU/L ± 29 versus 51 IU/L ± 1, respectively, p < 0.01) 
(Fig. 4A). Similarly, inflamed and injured liver cells usually leak increased levels of ALT into the 
bloodstream. With normal ALT levels being between 10-40 IU/L, db/db mice displayed significantly 
increased ALT levels as early as 7 weeks (> 50 IU/L) when compared to the db/+ control (<50 IU/L). This 
persisted throughout the experimental condition with results showing an increased in ALT at 13 and 
15 weeks respectively, when compared to the aged matched db/+ control (165 IU/L ± 42 versus 33 IU/L 
± 2, p < 0.001 and 159 IU/L ± 28 versus 43 IU/L ± 14, p < 0.01) (Fig. 4B). While AST and ALT can be used 
as a measure of liver damage, the ratio of AST/ALT provides an indication of the type of liver damage, 
with a high ratio (~ 2) associated with alcoholic liver disease, and a ratio lower than 1 associated with 
NAFLD [16]. The ratio of AST/ALT in db/db mice was less than 1 at 7 weeks (0.76 ± 0.07, p<0.05) and 
remained below 1 throughout (Fig. 4C), indicating the presence of hepatic steatosis. 
2.4.2. Haematoxylin and Eosin stain of paraffin-embedded liver sections 
While liver enzymes can be used as a marker of liver damage, histological analysis remains the 
gold standard confirming the onset of NAFLD. Haematoxylin and eosin stained liver sections indicated 
the presence of simple steatosis at 7 weeks. Additionally, results indicated that the severity of hepatic 
lipid accumulation increased with age. Microvesicular steatosis was identified at 7 weeks by the 
accumulation of multiple, small lipid droplets in hepatocytes, indicated by white arrows (Fig. 5B). At 
10 weeks microvesicular steatosis persisted, with an increased number of hepatocytes displaying lipid 
accumulation. By 13 weeks, intracellular lipid accumulation in the db/db group (Fig, 5F) led to 
hypertrophy with the nucleus of some cells displaced to the side of the cell. This phenomenon worsened 
by 15 weeks of age (Fig. 5H), where the steatosis appeared to be progressing towards macrovesicular 
steatosis, and lipid droplets within the cell merge into one, whilst the nucleus completely disintegrate. 
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Figure 4: Aspartate Transaminase and Alanine Transaminase levels in serum. Levels of 
Aspartate Transaminase (AST) (A), Alanine Transaminase (ALT) (B), and AST/ALT ratio (C) in serum 
of leptin receptor deficient mice (Leprdb/db) remained altered when compared to heterozygous lean 
controls (Leprdb/+) from 7 to 15 weeks of age. Results are presented as mean ± SEM, * p ≤ 0.05, ** p ≤ 0.01, 
***p ≤ 0.001 db/db versus age-matched db/+ control. 
7 10 13 15
0
50
100
150
200
250
db/+
db/db
****
Age of mice (weeks)
A
S
T
(I
U
/L
)
A 
B 
C 
Stellenbosch University  https://scholar.sun.ac.za
- 89 -
Figure 5: Haematoxylin and Eosin stained liver sections. Haematoxylin and Eosin stain on liver 
sections of lean (Leprdb/+) and obese (Leprdb/db) mice. Scale bar = 100 µm, white arrow = microvesicular 
steatosis. 
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2.5. Gene and Protein expression analysis 
2.5.1.1 De novo lipogenesis in liver 
Sterol regulatory element binding protein 1c is a transcription regulator associated with lipid 
metabolism and de novo lipid synthesis. Its main role as a transcriptional regulator is to regulate the 
expression of various hepatic lipid metabolism genes, including FASN, SCD, and HMGCR. In this study 
mRNA expression of SREBF1, was not significantly altered in db/db mice when compared to age-
matched db/+ controls at any of the selected time points (Fig. 6A). Nonetheless, mRNA expression for 
FASN, the enzyme that catalyses fatty acid synthesis, was significantly increased at 7 weeks in db/db 
mice when compared to db/+ controls (1.16 ± 0.18 compared to 0.25 ± 0.05, p < 0.01) and remained 
elevated (Fig. 6B). Similarly, mRNA expression of SCD1, an enzyme involved in the synthesis of 
monounsaturated fatty acids, was also significantly increased by 7 weeks in db/db mice when 
compared to db/+ controls (1.03 ± 0.08 compared to 0.20 ± 0.05, p < 0.001) and remained raised (Fig. 6C). 
Hydroxyl-3-Methylglutaryl-CoA Reductase is a rate-controlling enzyme in cholesterol biosynthesis 
that is known to increase LDL clearance, of which ApoB is the main protein constituent. In this study 
mRNA expression of HMGCR, was significantly increased at 7, 13 and 15 weeks in the db/db group 
when compared to db/+ controls (1.23 ± 0.13 compared to 0.49 ± 0.08, p < 0.001 and 1.06 ± 0.09 compared 
to 0.72 ± 0.05, p < 0.01 and 0.786 ±1.047 compared to 0.04 ± 085, p < 0.01 , respectively) (Fig. 6 D), while 
mRNA expression of ApoB remained the same (data not shown).  
2.5.1.2. Hepatic fatty acid oxidation 
Long-chain fatty acids, a known inducer of CPT1A modulate fatty acid β-oxidation through the 
activation of PPARα. In this study, the expression of PPARα was increased at 15 weeks, while CPT1A 
was decreased at 7 weeks when compared to db/+, no difference at any of the other time points was 
observed (Fig. 7A and B).  
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Figure 6: mRNA expression analysis of lipogenic genes in liver. mRNA epression analysis of 
Sterol regulatory element binding protein 1c (A), Fatty acid synthase (FASN) (B), Stearoyl-CoA 
Desaturas (SCD) (C) and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) (D) in livers of leptin 
receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age. 
Results are presented as mean ± SEM of n=8 animals per group. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
compared to age-matched control. 
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Figure 7: mRNA expression analysis of genes involved in β-Oxidation in liver. Relative mRNA 
expression of Peroxisome proliferator alpha (PPARα) (A), carnitine palmitoyl transferas (CPT1A) (B) of 
in livers of leptin receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 
weeks of age. Results are presented as mean ± SEM of n=8 animals per group. * p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001 compared to age-matched control. 
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2.5.2. Muscle insulin resistance 
Insulin signalling regulates glucose and lipid energy homeostasis, mainly via its action on the liver, 
skeletal muscle, and adipose tissue. This effect is mediated through activation of either the insulin-
dependent (PI3K/AKT) or insulin-independent (pAMPK) pathway. In this study, a significant increase 
in the ratio of pAKT/ tAKT (p<0.01) and pPI3K/tPi3K (p<0.01) was observed in db/db mice at 10 weeks 
when compared to the db/+ control (Fig. 8A and B). The expression of GLUT4 in the cytosolic fraction 
of skeletal muscle was increased at 15 weeks of age when compared to db/+ controls, though not 
significantly (Fig 8C). Protein expression of CPT1A, a marker of β-oxidation, was found to be is 
decreased at 10 and 13 weeks, though not significantly. However, at 15 weeks a significant reduction 
of CPT1A expression (p<0.01) was observed in the db/db group compared to the db/+ controls (Fig 8D). 
 
 
2.5.3. Cardiac gene expression analysis 
Obesity and insulin resistance are known inducers of glucolipotoxicity and has been positively 
correlated to oxidative stress, inflammation, fibrosis and apoptosis in cardiac cells. In this study, mRNA 
expression of NADPH Oxidase 4 (NOX4), a major source of oxidative stress, was increased in db/db 
mice when compared to db/+ controls, though not significantly (Fig. 9A). mRNA expression of NFκB, 
a transcription factor involved in inflammation and cell survival, was significantly increased from 10 
weeks onwards, in the db/db group when compared to db/+ controls (1.68 ± 0.09 compared to 0.69 ± 
0.04, p < 0.001) (Fig. 9B). Connective tissue growth factor (CTGF), a marker of fibrosis, also showed 
significantly increased mRNA expression in the obese db/db group when compared to db/+ controls 
(2.08 ± 0.39 compared to 0.98 ± 0.27, p < 0.001) at 15 weeks of age (Fig 9C). Similarly, Caspase 3 (CASP3), 
a known determinant of apoptosis was significantly increased in db/db mice when compared to db/+ 
controls (1.42 ± 0.10 compared to 1.06 ± 0.06, p < 0.05) at 10 weeks of age and remained elevated 
throughout the study (Fig. 9D). 
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Figure 8: Protein expression in skeletal muscle. Ratio of phosphorylated to total protein 
expression of p/t AKT (A), p/tPI3K (B), cytosolic GLUT4 (C) and CPT1A (D) in skeletal muscle of leptin 
receptor deficient mice (Leprdb/db) and heterozygous lean controls (Leprdb/+) from 7 to 15 weeks of age, 
normalised to β-actin as a loading control. Results are presented as mean ± SEM of n=6 animals per 
group, ** p ≤ 0.01 versus age-matched control. 
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Figure 9: mRNA expression of known determinants of oxidative stress, inflammation, fibrosis, 
and apoptosis in heart tissue of db/db mice. Relative mRNA expression of Nox4 (A), NFKB (B), CTGF 
(C) and CASP (3) in the heart of leptin receptor deficient mice (Leprdb/db) and heterozygous lean controls 
(Leprdb/+) from 7 to 15 weeks of age. Results are presented as mean ± SEM of n=8 animals per group. *p 
≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001 versus age-matched control. 
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3. Discussion 
Glucolipotoxicity: Results from both epidemiological and physiological studies have 
demonstrated that “glucolipotoxicity is a clinical consequence of endogenous glucose and lipid 
dysregulation, of which obesity is the major driver [17]. Not only does this increase the risk for 
developing T2DM, but also, there is a strong association with macro and microvascular complications. 
Currently glucolipotoxicity is one of the leading medical complications of modern society. Insulin 
resistance and NAFLD, as the predecessor of T2DM and cardiovascular dysfunction, are the main 
metabolic inducers of the “glucolipotoxicity”, which adversely affects the myocardium. The latter 
stems from the inability of insulin to inhibit lipolysis, thereby increasing FFA uptake into the 
hepatocytes. As a consequence, hepatic autoregulation is lost resulting in augmented hepatic de novo 
lipogenesis, inflammation, and gluconeogenesis, whilst concomitantly worsening peripheral IR. While 
it is well reported that IR causes hepatotoxicity, there is a paucity of data that supports the reverse. On 
the contrary, in this study we will present data that linked changes in body mass, FBG and augmented 
tryglecerides to hepatotoxicity, as the causality in the development of muscle IR and subsequent onset 
of CVD. 
 
Hepatic lipotoxicity induces insulin resistance: To date various studies have linked NAFLD to a 
wide spectrum of cardio vascular abnormalities, however the exact mechanism remains to be explored 
[18-22]. In this study, a leptin receptor deficient mouse model was employed. The aforementioned is a 
well-established and translatable model in the development of T2DM, in which, db/db mice become 
grossly obese, hyperglycaemic and hyperlipidaemic as early as 7 weeks of age, while displaying left 
ventricular dysfunction at 12 weeks [23-26] . Furthermore, db/db mice are frequently used as a murine 
model in the study of NAFLD, with db/db mice displaying increased aminotransferases [27,28]. Our 
study confirms previous findings showing that db/db mice presented with elevated body weight as 
early as 6 weeks, while fasting blood glucose levels were significantly increased by 8 weeks. This was 
accompanied by the classical trio of augmented serum hypertriglyceridemia, cholesterolaemia and 
LDL, a paradox of metabolic syndrome that is said to revolve around the development of hepatic IR. 
Certainly, studies have shown that peripheral IR plays a casual role in the development of hepatic 
steatosis [29-31]. However, in our study we showed that lipotoxicity was observed at 7 weeks in the 
absence of peripheral IR and that this was accompanied by increased liver AST and ALT enzymes, 
which are early markers of hepatocellular damage and are used as predictive measures to evaluate an 
individual’s  risk for developing NAFLD and T2DM. Furthermore, hepatic steatosis due to increased 
alcohol consumption is frequently linked with an AST/ALT ratio >1, however in patients with NAFLD 
the AST/ALT ratio is <1, and this has been particularly observed in obese, insulin resistant patients, 
with increased risk for CVD [16,32,33]. In our study, we showed that except for 9 weeks, db/db mice 
displayed a AST/ALT ratio of <1, which is indicative of simple steatosis and correlated with liver 
damage being evident in hepatic tissue from 7 weeks. The former effect occurred concurrent with 
increased lipid profiles. While AST and ALT are widely used to screen for NAFLD, some individuals 
may present with normal levels of liver enzymes throughout the disease progression [34] and therefore 
histological analysis remains the gold standard for the conclusive diagnosis of NAFLD [35]. Mild 
NAFLD presents histologically as simple steatosis that develops into macrovesicular changes as the 
disease progresses ([35,36]. Data presented in this study confirm this phenomenon where mice from 
the obese group presented with evidence of simple steatosis in the form of microvesicular lipid 
accumulation by the age of 7 weeks.  
 
Pathophysiology: NAFLD is considered as the hepatic manifestation of MetS and this has been 
associated with an enhanced expression of de novo lipogenic genes that activates a cascade of metabolic 
pathways that include the biosynthesis of saturated fatty acid, such as FASN and SCD-1 that is under 
the control of SREBF-1c. This was confirmed in the present study, where mice as early as 7 weeks 
presented with increased lipogenic genes. 
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Furthermore, increased β-oxidation in the liver has been associated with augmented CPT1A and 
PPAR-alpha (α) expression, which resulted in a decrease in triglycerides, aminotransferase, and liver 
steatosis. A study performed by Teng et al (2018) the author’s showed that CPT1A was increased in 
db/db mice at 20 weeks of age [37]. In the current study, we found that PPARα expression was increased 
in the db/db mice by 15 weeks of age, though there was no increase in CPT1 expression. We propose 
that expression might have been increased at a later time point, which may indicate the activation of 
an adaptive mechanism to combat lipid accumulation as observed by Trak-Smayra et al (2011) [28]. 
Interestingly, at this, stage no evidence of muscle insulin resistance or cardiac dysfunction were present 
and therefore we speculate that in the current model NAFLD might be the main driver of muscle IR 
and subsequent CVD. 
 
Onset of muscle insulin resistance: In support of the causal role, we further investigated muscle 
IR. In the obese state, dyslipidaemia causes chronic low-grade inflammation, which is accompanied by 
an increased release of FFA into the circulation including peripheral tissue. Augmented FFA uptake 
results in the generation of excess ceramide and diacylglycerol (DAG), which in turn activates PKCθ. 
Increased PKC promote the phosphorylation of IRSSer307. This results in the inhibition of pPI3K/pAKT 
complex to inhibit glycogen synthesis while increasing GLUT4 tranlocation to the plasma membrane. 
This was confirmed in a study done by Sharma et al (2015), who observed decreased phosphorylation 
of IRS, PI3K, and AKT, in db/db mice at 12 weeks [38], while Zheng et al (2015) demonstrated the 
presence of IR at 16 weeks [39]. In this study, we showed that muscle IR developed at 10 weeks as 
confirmed by phosphorylation of PI3K/AKT with concomitant increase in cytosolic GLUT4 expression.  
 
Onset of cardiac dysfunction: With 425 million individuals living with diabetes and 1.6 million 
being obese, a reduced life expectancy is anticipated with a catastrophic rise in cardiovascular related 
deaths will occur within the next decade. This increase is directly associated with glucolipotoxicity that 
modulates key signal transduction genes associated with oxidative stress, inflammation, fibrosis, and 
apoptosis, with deleterious consequences to the myocardium. Glucolipotoxicity is worsened with the 
manifestation of NAFLD and IR, due to the inability of insulin to suppress endogenous hepatic glucose 
production and the failure of insulin to increase peripheral glucose uptake. These overarching changes 
in glucose and lipid metabolism, whether a cause or consequence of NAFLD, contribute towards the 
observed metabolic changes and accelerated cardiac phenotype present in diabetic individuals. In this 
study, we showed that hepatic lipotoxicity preceded muscle IR and that this deleterious action 
contributes towards an increased NADPH oxidase-dependant generation of ROS with an associated 
increase in the inflammatory response. It has been postulated that this metabolic pattern favours 
increased apoptosis, promotes collagen formation and augmented fibrosis with a reduced cardiac 
functional phenotype. In this study, we showed that an increased collagen cross-linking directly 
contributes towards a loss of myocardial contractility as demonstrated with increased CTGF expression 
and subsequent reduced ejection fraction at 13 weeks.  
 
In conclusion, contradictory evidence still exists regarding the order of onset of NAFLD and IR. 
However, the current study provides strong evidence of the casual role NAFLD plays in the 
development of muscle IR, and subsequent time dependant onset of cardiac dysfunction. Nonetheless, 
we speculate that the observed effect is dependent on various factors, which include 1) the model under 
investigation and 2) genetics. In NAFLD, two phenotypes exist, “genetic” and “metabolic”. We 
hypothesize that in a genetically modified model such as the db/db mouse model used in this study, IR 
is a consequence of NAFLD, whereas during a “metabolic insult,” in the form of a “high-fat-high-sugar 
diet”, IR will precede and contribute to the development of NAFLD. Although the latter feature was 
not investigated in the present study, we propose that the disease model used plays an imperative role 
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in delineating the order of onset, with the order of appearance of these risk factors being important and 
should be taken into consideration to develop effective therapeutics.  
 
4. Materials and Methods:  
4.1. Animals sample size and randomization  
Four-week-old C57BLKS/J homozygous Leprdb/db mice (db/db) and their heterozygous Lepr 
nondiabetic lean controls (db/+) were obtained from Jackson’s Laboratories (Sacramento, USA). 
Animals were housed at the Primate Unit and Delft Animal Centre (PUDAC) of the South African 
Medical Research Council (SAMRC) in a controlled environment with a 12 h light/dark cycle in a 
temperature range of 23-25ºC (relative humidity: ∼50%). The mice received standard laboratory chow 
pellets (Afresh Vention, Cape Town, RSA) ad libitum and had free access to water. At 6 weeks, mice 
were divided into two groups based on their genetic background; db/+ (lean) (n=32) or db/db (obese) 
(n=32) group, each group was further divided into 4 subgroups (week 7, 10, 13, 15) with n=8 animals 
per group. For each subgroup, 4 hour fasting blood glucose (FBG), body weights and echocardiography 
analysis were performed at week 7, 10, 13, and 15. Upon termination after the allotted time, serum, 
heart and liver samples were collected for lipid profile, liver enzyme, as well as gene and protein 
expression analysis. Ethical clearance for the animal study was obtained from the South African 
Medical Research Council (SAMRC), Ethics Committee for Research on Animals (ECRA/05/15). 
 
4.2. Echocardiography analysis  
The mice were anaesthetised with 1.0-2.5% isoflurane and positioned in the supine position on a 
warming pad. Closed chest echocardiography was performed with a VEVO 2100 ultrasound system 
(Fujifilm, Visualsonics, Ontario, Canada) and a 30 MHz linear array transducer at the respective time 
intervals. Left ventricular ejection fraction (EF), as a measurement of cardiac dysfunction, was obtained 
from 2-dimensional and M-mode measurements at the mid-papillary level. All measurements were 
made off-line on the mean of at least three consecutive cardiac cycles with the software resident on the 
ultrasound system. 
 
4.3. Lipid profile and liver enzyme analysis 
After the predetermined experimental conditions, 4 hour fasted mice were weighed and 
anesthetized with halothane before blood was collected from the abdominal vena cava for subsequent 
lipid profile analysis. Blood was centrifuged at 4, 000 g at 4ºC for 15 min before the serum was removed 
and sent to PathCare Medical Diagnostic Laboratories (Cape Town, RSA) for total cholesterol, 
triglycerides, LDL, high-density lipoprotein (HDL) analyses as well as liver enzyme (Alanine 
aminotransferase (ALT) and Aspartate aminotransferase (AST)) analysis. 
 
4.4. Histopathological analysis 
Snap-frozen tissue were cut into 10 µm sections using a cryostat and attached to 
aminopropyltriethoxysilane coated glass slides (Sigma-Aldrich Corp., St. Louis) and then stained with 
hematoxylin and eosin stain (Merck-Millipore, Billerica, USA) to assess hepatic steatosis, as per 
manufacturer’s instructions. For histopathological analysis, 5 random microscopic fields were captured 
and visualized using a Nikon Eclipse Ti inverted microscope (Tokyo, Japan).  
 
4.5. Quantitative Real-Time polymerase chain reaction analysis (QRT-PCR) 
Total RNA was extracted from rat heart tissue using TRrizol reagent (ThermoFisher Scientific, Inc., 
Waltham, MA, USA), while the Turbo DNase Kit (ThermoFisher Scientific, Inc.,Waltham, MA, USA) 
was used to remove genomic DNA, as per manufacturer’s instructions. RNA integrity was determined 
using an Agilent 2100 Bioanalyser (Agilent Technologies, Inc., Palo Alto, CA, USA), according to 
manufacturer’s instructions. First strand synthesis was done using a Superscript first strand cDNA 
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synthesis kit (ThermoFisher Scientific, Inc., Waltham, MA, USA), as per manufacturer's instructions. 
Predesigned and optimized TaqMan gene expression probes were used for differential gene expression 
(ThermoFisher Scientific, Inc., Waltham, MA, USA). 
 
4.6. Western blot analysis 
Proteins were extracted as previously described [40]. Twenty micrograms of protein lysate were 
denatured and loaded onto a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride 
membrane. Nonspecific binding on the membranes was blocked, using 5% w/v low-fat milk in Tris-
buffered saline with Tween-20. Subsequently, the membrane was incubated overnight at 4°C with Cell 
Signaling (Beverly, MA, USA) primary antibodies: Phosphatidylinositol-4,5-bisphosphate 3-kinase 
(anti-tPI3K; 1:1000 dilution), anti-pPI3K (1:1000), Protein kinase B  (anti-tAKT; 1:1000), anti-pAKT 
(1:1000), 5' AMP-activated protein kinase (tAMPK; 1:1000), pAMPK(Thr172) (1:1000), Glucose 
transporter type 4 (GLUT-4; 1:1000) and carnitine palmitoyltransferase (CPT1; 1:1000) (Sigma ), with 
the relevant horseradish peroxidase-conjugated secondary antibodies applied the following day for 90 
min at room temperature. β-Actin (1:2000) antibody was added as a loading control. Proteins were 
detected and quantified using a Chemidoc-XRS imager and Quantity One software (Bio-Rad 
Laboratories, Hercules, CA, USA). 
 
4.7. Statistical Analysis 
Data are expressed as the mean±standard error of the mean (SEM). Statistical analysis was 
performed using GraphPad Prism (Version 5.01, CA, USA). Groups of data were compared with a one-
way analysis of variance (ANOVA) followed by Dunnet’s Multiple Comparison tests. The unpaired, 
two-tailed student t-test was used when only two groups were compared. Values of p<0.05 were 
regarded as significant.  
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9. Abbreviations 
PPARα  Peroxisome proliferator alpha 
IR   Insulin resistance 
NAFLD  non-alcoholic fatty liver disease  
Leprdb/db   Leptin receptor-deficient diabetic   
Leprdb/+  Leptin receptor-deficient control  
SREBP-1c  Sterol regulatory element binding protein 1c  
ChREBP  Carbohydrate responsive element-binding protein  
CPT1A  Carnitine palmitoyl transferasE 
FBG  Fasting Blood Glucose 
T2DM  Type 2 diabetes mellitus 
FFA   Free fatty acid  
FASN  Fatty acid synthase  
SCD  Sterol-CoA Desaturase 
HMGCR Hydroxy-3-Methylglutaryl-CoA Reductase  
HOMA-IR Homeostasis Model of Assessment  
EF   Ejection Fraction 
β-Oxidation Beta-Oxidation  
CVD  Cardiovascular Disease 
LDL  Low-density lipoprotein 
HDL  High-density lipoprotein  
ALT  Alanine aminotransferase 
AST  Aspartate aminotransferase 
QRT-PCR Quantitative Real-Time polymerase chain reaction analysis  
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